Unnamed: 0,title,date,stock,sentiment
933074.0,"The Daily Biotech Pulse: Sorrento Submits EUA Application For Rapid Coronavirus Test, Decision Day For Viela, Lantern Pharma IPO",2020-06-11 08:12:00-04:00,NVO,neutral
933075.0,"Novo Nordisk Reports Weight Loss Of 14.9% In STEP 1 Trial, Says Met Both Primary Endpoints",2020-06-04 13:12:00-04:00,NVO,negative
933076.0,"The Daily Biotech Pulse: FDA Nod For Roche's Combo Therapy In Liver Cancer, Allena Rips Higher, Pfizer To Invest Up To $500M In Biotechs",2020-06-02 07:45:00-04:00,NVO,negative
933077.0,Stocks That Hit 52-Week Highs On Monday,2020-06-01 10:41:00-04:00,NVO,neutral
933078.0,"Shares of several healthcare companies are trading higher amid market strength. Strength potentially related to coronavirus efforts including testing, vaccine development and treatment measures from several names in the sector.",2020-05-28 12:33:00-04:00,NVO,positive
933079.0,'List of external participants expected at Rose Garden event starting momentarily where @POTUS will announce @MedicareGov patients will be provided with new choices of Part D plans for insulin at no more than $35 for a month's supply.' -Steve Herman Tweet,2020-05-26 16:13:00-04:00,NVO,negative
933080.0,"The Daily Biotech Pulse: Mixed Filgotinib Readout For Gilead-Galapagos, Akorn To File For Chapter 11, D-Day For Aquestive",2020-05-21 08:01:00-04:00,NVO,neutral
933081.0,Stocks That Hit 52-Week Highs On Wednesday,2020-05-20 10:38:00-04:00,NVO,neutral
933082.0,Novo Nordisk Option Alert: Jan 15 $75 Calls Sweep (34) near the Ask: 327 @ $1.351 vs 11 OI; Ref=$63.9799,2020-05-18 15:09:00-04:00,NVO,positive
933083.0,"Novo Nordisk Shares Quiet Following Press Release Co.'s Semaglutide 2.4 mg Shows Superior, Sustained Weight Loss vs Placebo",2020-05-13 11:42:00-04:00,NVO,positive
933084.0,"The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle",2020-05-06 08:42:00-04:00,NVO,positive
933085.0,Novo Nordisk Sales Rose by 16% in Q1 2020,2020-05-06 05:12:00-04:00,NVO,neutral
933086.0,"The Daily Biotech Pulse: Inovio's MERS Vaccine Data, Fast Track Designation For Erytech, FDA Approves Higher Dose Of Merck's Keytruda",2020-04-29 08:40:00-04:00,NVO,positive
933087.0,Stocks That Hit 52-Week Highs On Tuesday,2020-04-28 10:18:00-04:00,NVO,neutral
933088.0,"The Daily Biotech Pulse: Pfizer Earnings, Roche's Spinal Muscular Dystrophy Treatment, Moderna COVID-19 Vaccine Update",2020-04-28 07:36:00-04:00,NVO,neutral
933089.0,Stocks That Hit 52-Week Highs On Monday,2020-04-27 10:21:00-04:00,NVO,neutral
933090.0,"The Daily Biotech Pulse: FDA Approves Sanofi's Meningococcal Vaccine, Pluristem Secures $54M In Funding For COVID-19 Treatment, Oric Pharma Prices IPO",2020-04-24 08:38:00-04:00,NVO,positive
933091.0,Stocks That Hit 52-Week Highs On Thursday,2020-04-23 10:41:00-04:00,NVO,neutral
933092.0,"The Daily Biotech Pulse: Applied DNA Begins Validating COVID-19 Test, Cara's Positive Readout, Novan Explores Strategic Alternatives",2020-04-21 08:19:00-04:00,NVO,positive
933093.0,Shares of several healthcare companies are trading higher. Strength could potentially be related to the increased demand in medical products stemming from the coronavirus pandemic.,2020-04-16 12:38:00-04:00,NVO,positive
933094.0,Novo Nordisk Receives Health Approval For Rybelsus As Treatment Option To Improve Glycemic Control In Adults With Type 2 Diabetes Mellitus,2020-04-09 08:05:00-04:00,NVO,positive
933095.0,Shares of several healthcare companies are trading higher as the market rebounds on extended measures to help curb the coronavirus. NOTE: The sector could also be trading higher due to increased demand for medical products amid the coronavirus outbreak.,2020-03-30 10:17:00-04:00,NVO,positive
933096.0,"Novo Nordisk shares are trading higher, notable above other healthcare names, not currently seeing company-specific news. Markets have been volatile over past few sessions amid US stimulus legislation.",2020-03-26 09:01:00-04:00,NVO,positive
933097.0,20 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2020-03-25 07:35:00-04:00,NVO,neutral
933098.0,"Shares of several healthcare companies are trading higher the Fed announced actions to support the U.S. economy. The Fed will do open-ended treasury, mortgage-backed securities and will buy $375 billion in treasury this week.",2020-03-23 11:07:00-04:00,NVO,positive
933099.0,Novo Nordisk Pauses The Clinical Trials Investigating Concizumab In Haemophilia A And B With Or Without Inhibitors As A Result Of Non-Fatal Thrombotic Events In Three Patients,2020-03-16 14:06:00-04:00,NVO,positive
933100.0,Shares of several healthcare companies are trading lower in sympathy with the overall market on continued downward momentum caused by the coronavirus. The virus has had a negative impact on the global economy.,2020-03-16 09:40:00-04:00,NVO,negative
933101.0,Shares of several healthcare companies are trading higher as the market rebounds following Thursday's selloff. NOTE: Since the coronavirus outbreak the healthcare sector has been extremely volatile.,2020-03-13 09:29:00-04:00,NVO,positive
933102.0,Shares of several healthcare companies are trading lower as equities sell off amid continued global coronavirus concerns. The virus has caused global economic disruption and negatively impacted stocks across sectors.,2020-03-12 09:26:00-04:00,NVO,negative
933103.0,Shares of several healthcare companies are trading lower. Movement appears market related amid selloff in equities. The global coronavirus outbreak has caused volatility in global markets and impacted stocks across sectors.,2020-03-11 07:15:00-04:00,NVO,neutral
933104.0,52 Healthcare Stocks Moving In Monday's Pre-Market Session,2020-03-09 08:04:00-04:00,NVO,neutral
933105.0,Shares of several healthcare-related companies are trading higher after Joe Biden secured several key wins in Super Tuesday. Biden's more 'moderate' healthcare policies have been seen as more favorable for the sector.,2020-03-04 07:16:00-05:00,NVO,positive
933106.0,Novo Nordisk Option Alert: Mar 20 $60 Calls Sweep (2) near the Ask: 500 @ $2.451 vs 464 OI; Earnings 5/1 Before Open [est] Ref=$60.09,2020-03-02 10:56:00-05:00,NVO,positive
933107.0,"Novo Nordisk shares are trading higher, not currently seeing company-specific news. NOTE: Several healthcare stocks are trading higher for the session.",2020-03-02 09:12:00-05:00,NVO,positive
933108.0,Shares of several healthcare and biotech companies are trading lower amid continued spread of coronavirus including notable upticks in Iran and Italy. NOTE: The virus has raised fear of a global economic slowdown.,2020-02-24 08:37:00-05:00,NVO,negative
933109.0,"The Daily Biotech Pulse: Tonix Slumps On Failed Study, Applied Genetic Announces Offering, Beam Therapeutics, PPD Price IPOs",2020-02-06 07:47:00-05:00,NVO,negative
933110.0,13 Key NASH Drug Candidates To Watch For In A Potential $30-Billion Market,2020-02-05 16:11:00-05:00,NVO,neutral
933111.0,Stocks That Hit 52-Week Highs On Wednesday,2020-02-05 10:16:00-05:00,NVO,neutral
933112.0,Novo Nordisk shares are trading higher following Q4 results. The company reported a 9% year-over-year increase in overall revenue and a 9.8% increase in diabetes/obesity care revenues.,2020-02-05 09:15:00-05:00,NVO,positive
933113.0,"The Daily Biotech Pulse: Merck Spins Off Slow-Growth Businesses, ZioPharm Announces Offering, PhaseBio Data",2020-02-05 07:43:00-05:00,NVO,neutral
933114.0,"Earnings Scheduled For February 5, 2020",2020-02-05 04:26:00-05:00,NVO,neutral
933115.0,Novo Nordisk's Rybelsus Recommended For Approval For Treatment Of Adults With Type-2 Diabetes By European Regulatory Authorities,2020-01-31 06:15:00-05:00,NVO,positive
933116.0,Novo Nordisk Reports Partnership With HighRes Biosolutions To Transform Drug Discovery In Automated Lab,2020-01-24 09:05:00-05:00,NVO,neutral
933117.0,Novo Nordisk Option Alert: Feb 21 $65 Calls Sweep (6) near the Ask: 1026 @ $0.497 vs 2637 OI; Earnings 2/5 Before Open Ref=$61.62,2020-01-23 15:03:00-05:00,NVO,positive
933118.0,"B of A Securities Reiterates Neutral on Novo Nordisk, Raises Price Target to $440",2020-01-17 08:45:00-05:00,NVO,positive
933119.0,"The Daily Biotech Pulse: Novo Nordisk's Ozempic Receives Label Expansion For Cardiovascular Events, Adcom Disappointment Inflicts Pain On Durect Shares",2020-01-17 08:07:00-05:00,NVO,negative
933120.0,Novo Nordisk Confirms That Its Rybelsus Diabetes Pill Will Be Covered by Express Scripts,2020-01-17 05:38:00-05:00,NVO,neutral
933121.0,Novo Nordisk Says FDA Also Updated Rybelsus Label To Include Additional Information From Pioneer 6 CVOT Demonstrating CV Safety; Says Rybelsus Demonstrated CV Safety By Meeting Primary Endpoint Of Non-inferiority For Composite Mace Endpoint,2020-01-16 17:42:00-05:00,NVO,positive
933122.0,Novo Nordisk Announces Ozempic Approved In US For CV Risk Reduction In People With Type 2 Diabetes And Established CVD,2020-01-16 17:41:00-05:00,NVO,positive
933123.0,"The Daily Biotech Pulse: Osmotica Soars On Insider Buys, Ultragenyx's Partnered Rare Disease Drug Moves Into Clinics",2020-01-16 07:22:00-05:00,NVO,neutral
933124.0,Stocks That Hit 52-Week Highs On Wednesday,2020-01-15 13:14:00-05:00,NVO,neutral
933125.0,Novo Nordisk A/S shares are trading higher on seemingly no company-specific news to justify the price action.,2020-01-15 09:17:00-05:00,NVO,neutral
933126.0,"The Daily Biotech Pulse: Nektar Withdraws Opioid Pain Drug NDA, Galapagos Takes Stake In Fibrocor, Integra Lifesciences Lowers Q4 Guidance",2020-01-15 08:22:00-05:00,NVO,negative
933127.0,34 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2020-01-15 08:10:00-05:00,NVO,neutral
933128.0,"The Daily Biotech Pulse: PhaseBio To Buy Hypertension Asset, Stemline Falls On Q4 Pre-Announcement, FDA Panel To Review Nektar's Opioid Drug",2020-01-14 07:55:00-05:00,NVO,positive
933129.0,Stocks That Hit 52-Week Highs On Friday,2020-01-10 12:18:00-05:00,NVO,neutral
933130.0,Novo Nordisk shares are trading higher. The stock reached a 52-week high today. Not seeing any news to justify the price action.,2020-01-10 11:04:00-05:00,NVO,positive
933131.0,FDA Approves Novo Nordisk's Fiasp For Treatment Of Children With Diabetes,2020-01-06 09:07:00-05:00,NVO,positive
933132.0,Novo Nordisk shares are trading lower after Guggenheim Securities downgraded the stock from Buy to Neutral.,2020-01-03 09:44:00-05:00,NVO,positive
933133.0,Guggenheim Securities Downgrades Novo Nordisk to Neutral,2020-01-03 06:41:00-05:00,NVO,positive
933134.0,Novo Nordisk Announces 'My$99Insulin' Program And Other Insulin Affordability Measures,2020-01-02 09:35:00-05:00,NVO,neutral
933135.0,21 Healthcare Stocks Moving In Thursday's Pre-Market Session,2020-01-02 07:49:00-05:00,NVO,neutral
933136.0,Stocks That Hit 52-Week Highs On Friday,2019-12-27 11:27:00-05:00,NVO,neutral
933137.0,Novo Nordisk Option Alert: Jan 17 $60 Calls Sweep (36) near the Ask: 902 @ $0.5 vs 4805 OI; Earnings 1/31 Before Open [est] Ref=$58.0899,2019-12-26 13:12:00-05:00,NVO,positive
933138.0,"The Daily Biotech Pulse: Positive Adcom Verdict For Merck, Homology Medicine Slips On Mixed Gene Therapy Efficacy Data",2019-12-18 07:23:00-05:00,NVO,positive
933139.0,"The Daily Biotech Pulse: Roche Gets US Antitrust Clearance For Spark Purchase, An Orphan Drug Designation For Prevail, Dynavax Names CEO",2019-12-17 07:56:00-05:00,NVO,positive
933140.0,Shares of several healthcare stocks are trading lower as US equities dip following escalating US-China tensions over Hong Kong. US Stocks further fell on worse-than-expected manufacturing data.,2019-12-02 11:31:00-05:00,NVO,negative
933141.0,Novo Nordisk shares are trading higher. Not currently seeing any company-specific news.,2019-11-25 09:22:00-05:00,NVO,positive
933142.0,"Trump Says he Will Release a Plan to Let States Import Prescription Drugs Which are ""MUCH CHEAPER""",2019-11-22 14:08:00-05:00,NVO,neutral
933143.0,19 Healthcare Stocks Moving In Friday's Pre-Market Session,2019-11-22 07:47:00-05:00,NVO,neutral
933144.0,"Novo Nordisk shares are trading lower. NOTE: The company earlier presented at its 2019 Capital Markets day, giving growth guidance and financial targets.",2019-11-20 11:12:00-05:00,NVO,positive
933145.0,13 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2019-11-20 07:45:00-05:00,NVO,neutral
933146.0,"The Daily Biotech Pulse: Endo's Cellulite Treatment Accepted For Review, Diffusion Pharma Reports Positive Glioblastoma Data",2019-11-20 07:25:00-05:00,NVO,positive
933147.0,Novo Nordisk Expects to Meet Its Current Long-term Financial Targets and Introduces Strategic Aspirations at the Capital Markets Day 2019,2019-11-20 04:58:00-05:00,NVO,neutral
933148.0,Novo Nordisk EVP for Commercial Strategy and Corporate Affairs Says Co Expects to Increase Its Diabetes Market Share to More Than a Third by 2025 From 28% Today,2019-11-20 04:55:00-05:00,NVO,positive
933149.0,"The Daily Biotech Pulse: Therapix To Reverse Merge With CBD Company, Crispr Gene Editing Therapy Readout",2019-11-19 07:56:00-05:00,NVO,neutral
933150.0,UBS Downgrades Novo Nordisk to Neutral,2019-11-18 10:41:00-05:00,NVO,neutral
933151.0,"Benzinga's Top Upgrades, Downgrades For November 18, 2019",2019-11-18 09:48:00-05:00,NVO,positive
933152.0,Barclays Upgrades Novo Nordisk to Overweight,2019-11-18 06:11:00-05:00,NVO,negative
933153.0,"Dicerna, Novo Nordisk Enter Agreement to Discover and Develop RNAi Therapies for Liver-Related Cardio-Metabolic Diseases",2019-11-18 06:01:00-05:00,NVO,positive
933154.0,"The Daily Biotech Pulse: Amarin Gets Unanimous Backing For Vascepa Expansion, BeiGene's Blood Cancer Drug Gets Approval",2019-11-15 07:08:00-05:00,NVO,negative
933155.0,Novo Nordisk Option Alert: Dec 20 $60 Calls Sweep (2) near the Ask: 500 @ $0.801 vs 4043 OI; Ref=$57.245,2019-11-12 11:10:00-05:00,NVO,positive
933156.0,5 Healthcare Stocks Moving In Monday's Pre-Market Session,2019-11-11 07:42:00-05:00,NVO,neutral
933157.0,Novo Nordisk Obtains Exclusive Worldwide Licence to Potential NASH Candidate UD-014 From Ube Industries,2019-11-07 03:57:00-05:00,NVO,positive
933158.0,Novo Nordisk Earlier Reported DKK15B Buyback,2019-11-06 08:45:00-05:00,NVO,neutral
933159.0,Novo Nordisk shares are trading higher after the company reported better-than-expected Q3 EPS and sales results.,2019-11-01 10:30:00-04:00,NVO,positive
933160.0,26 Stocks Moving in Friday's Pre-Market Session,2019-11-01 08:03:00-04:00,NVO,neutral
933161.0,"Earnings Scheduled For November 1, 2019",2019-11-01 06:50:00-04:00,NVO,neutral
933162.0,"The Daily Biotech Pulse: Agile Receives Favorable Adcom Verdict, Merit Medical Tumbles On Earnings, 2 Biotechs To Debut",2019-10-31 08:08:00-04:00,NVO,positive
933163.0,"The Daily Biotech Pulse: Novartis Program Placed On Partial Clinical Hold, Adcom Snub For Amag, Amgen Earnings",2019-10-30 07:01:00-04:00,NVO,negative
933164.0,"The Daily Biotech Pulse: Mirati Tastes Success With KRAS Inhibitor, Roche-Spark Deal Delayed Further, Morphosys Halts Study",2019-10-29 07:32:00-04:00,NVO,positive
933165.0,More Earnings And A Fed Decision In Week Four Of The WeTrader Competition,2019-10-28 11:56:00-04:00,NVO,neutral
933166.0,"The Daily Biotech Pulse: Melinta Crosses FDA Hurdle But Sees Liquidity Pushback, Positive Readout For Aclaris Wart Drug",2019-10-25 07:12:00-04:00,NVO,positive
933167.0,FDA Approves Novo Nordisk's Expanded Label For Fiasp To Include Use In Insulin Infusion Pumps For Improving Glycemic Control In Adults With Type 1/Type 2 Diabetes,2019-10-22 09:15:00-04:00,NVO,positive
933168.0,Novo Nordisk Option Alert: Nov 15 $55 Calls Sweep (42) near the Ask: 3000 @ $0.5 vs 377 OI; Earnings 11/1 Before Open Ref=$52.33,2019-10-18 12:08:00-04:00,NVO,positive
933169.0,14 Healthcare Stocks Moving In Thursday's Pre-Market Session,2019-10-17 07:42:00-04:00,NVO,neutral
933170.0,9 Healthcare Stocks Moving In Monday's Pre-Market Session,2019-10-14 07:54:00-04:00,NVO,neutral
933171.0,16 Healthcare Stocks Moving In Friday's Pre-Market Session,2019-10-04 08:21:00-04:00,NVO,neutral
933172.0,Attention Biotech Investors: Mark Your Calendar For These October PDUFA Dates,2019-09-30 16:32:00-04:00,NVO,neutral
933173.0,Novo Nordisk to Price New Diabetes Pill at Level With Its Injectable Ozempic Drug,2019-09-23 03:54:00-04:00,NVO,neutral
933174.0,Shares of several drug companies are trading higher after Senate Majority Leader McConnell suggested a new Democratic drug price reform proposal would be dead on arrival.,2019-09-20 13:00:00-04:00,NVO,negative
933175.0,FDA Approves Novo Nordisk's Rybelsus Oral Tablets,2019-09-20 10:35:00-04:00,NVO,positive
933176.0,"The Daily Biotech Pulse: FDA Approves Merck HIV Drugs, Five Prime CEO Quits, HTG Molecular Announces Secondary Offering",2019-09-20 07:46:00-04:00,NVO,positive
933177.0,18 Healthcare Stocks Moving In Thursday's Pre-Market Session,2019-09-19 08:19:00-04:00,NVO,neutral
933178.0,"UPDATE: Novo Nordisk Says Primary Endpoint, Rate Of Overall Symptomatic Hypoglycaemia In Maintenance Period Of 36 Weeks Which Was Tested For Superiority, Was Numerically Lower But Not Statistically Significant Versus Insulin Glargine U300",2019-09-19 06:16:00-04:00,NVO,negative
933179.0,Novo Nordisk Reports Tresiba Showed An Overall Lower Risk Of Hypoglycaemia And Significantly Lower HBA1C When Compared To Insulin Glargine U300 In People With Type 2 Diabetes,2019-09-19 06:16:00-04:00,NVO,negative
933180.0,"Benzinga's Top Upgrades, Downgrades For September 17, 2019",2019-09-17 10:38:00-04:00,NVO,positive
933181.0,9 Healthcare Stocks Moving In Tuesday's Pre-Market Session,2019-09-17 08:13:00-04:00,NVO,neutral
933182.0,25 Stocks Moving in Tuesday's Pre-Market Session,2019-09-17 07:42:00-04:00,NVO,neutral
933183.0,Novo Nordisk shares are trading higher after Citigroup upgraded the company's stock from Neutral to Buy.,2019-09-17 07:05:00-04:00,NVO,positive
933184.0,Citigroup Upgrades Novo Nordisk to Buy,2019-09-17 06:38:00-04:00,NVO,neutral
933185.0,"Medtronic, Novo Nordisk Enter Agreement to Provide Integrated Digital Solutions for People with Diabetes",2019-09-16 03:52:00-04:00,NVO,positive
933186.0,"The Week Ahead In Biotech: Novo Nordisk And Merck Await FDA Rulings, 2 IPOs On Deck",2019-09-15 11:18:00-04:00,NVO,positive
933187.0,"Bank of America Reiterates Neutral on Novo Nordisk, Raises Price Target to $400",2019-09-13 08:02:00-04:00,NVO,neutral
933188.0,Novo Nordisk A/S shares are trading higher on seemingly no company-specific news. The stock could potentially be rebounding as the stock has been down ~4% over the past few days.,2019-09-11 12:24:00-04:00,NVO,neutral
933189.0,Shares of several drugmakers are trading lower on news of a drug pricing bill being developed by House Democrats. The proposed bill would set US drug prices based on prices in other wealthy countries.,2019-09-10 10:30:00-04:00,NVO,positive
933190.0,Novo Nordisk A/S shares are trading lower on seemingly no company-specific news.,2019-09-10 10:17:00-04:00,NVO,negative
933191.0,22 Healthcare Stocks Moving In Tuesday's Pre-Market Session,2019-09-10 09:02:00-04:00,NVO,neutral
933192.0,Novo Nordisk shares are trading lower. Not seeing any news to justify the price action.,2019-09-09 10:40:00-04:00,NVO,neutral
933193.0,"The Daily Biotech Pulse: Cheery Results For Sage's Depression Drug, UniQure Offering, Axsome Aces Study Of Headache Drug",2019-09-05 08:12:00-04:00,NVO,neutral
933194.0,"Benzinga's Top Upgrades, Downgrades For August 30, 2019",2019-08-30 09:35:00-04:00,NVO,positive
933195.0,18 Healthcare Stocks Moving In Friday's Pre-Market Session,2019-08-30 08:43:00-04:00,NVO,neutral
933196.0,Novo Nordisk A/S shares are trading lower after Jefferies downgraded the stock from Hold to Underperform.,2019-08-30 08:29:00-04:00,NVO,neutral
933197.0,Jefferies Downgrades Novo Nordisk to Underperform,2019-08-30 06:35:00-04:00,NVO,neutral
933198.0,Attention Biotech Investors: Mark Your Calendar For These September PDUFA Dates,2019-08-28 08:02:00-04:00,NVO,neutral
933199.0,Novo Nordisk A/S shares are trading higher after the European Commission granted an extension of the indication for Fiasp for the management of diabetes in adolescents and children aged one year and above.,2019-08-22 09:00:00-04:00,NVO,positive
933200.0,12 Healthcare Stocks Moving In Thursday's Pre-Market Session,2019-08-22 08:47:00-04:00,NVO,neutral
933201.0,Novo Nordisk Announces Fiasp Approved in Europe for the Management of Diabetes in Adolescents and Children Aged One Year and Above,2019-08-22 04:15:00-04:00,NVO,positive
933202.0,Novo Nordisk  Files Lawsuit Against Mylan for Patent Infringement of Victoza Diabetes Drug,2019-08-22 04:14:00-04:00,NVO,negative
933203.0,"Shares of healthcare companies are trading higher as US markets rebound from recent weakness following a yield curve inversion, which caused recession fears. Trump also recently announced the US would delay China tariffs, renewing hopes of a trade deal.",2019-08-16 13:27:00-04:00,NVO,negative
933204.0,Shares of several large-cap companies are trading higher with the broader market on renewed optimism surrounding US-China trade talks after Donald Trump announced earlier in the week that he would delay additional tariffs on Chinese goods until December.,2019-08-16 11:53:00-04:00,NVO,positive
933205.0,"Novo Nordisk Faces Suit In Danish Court, Investors Demand 11.8B Danish Crowns In Compensation For Alleged Stock Manipulation",2019-08-16 07:38:00-04:00,NVO,negative
933206.0,"Shares of several healthcare companies are trading lower in sympathy with the overall market after the spread between the 2-year and 10-year yield curve inverted for the first time since 2007, potentially signaling an oncoming recession.",2019-08-14 11:17:00-04:00,NVO,negative
933207.0,Shares of several large-cap companies are trading higher in sympathy with the overall market after the U.S. announced it is excluding and delaying the additional 10% tariff on certain products.,2019-08-13 10:37:00-04:00,NVO,positive
933208.0,Novo Nordisk's Operating Profit Increased by 12% in Danish Kroner and by 6% at Constant Exchange Rates in First Six Months of 2019,2019-08-09 04:09:00-04:00,NVO,positive
933209.0,"Novo Nordisk Buys Factory in North Carolina to Produce Oral Semaglutide, Other Oral Products",2019-08-06 04:03:00-04:00,NVO,neutral
933210.0,e-Therapeutics Extends Research Collaboration with Novo Nordisk,2019-08-01 03:33:00-04:00,NVO,positive
933211.0,28 Healthcare Stocks Moving In Today's Pre-Market Session,2019-07-31 09:41:00-04:00,NVO,neutral
933212.0,Novo Nordisk Says Is Committed To Ensuring Patients' Medicine Supplies Are Unaffected Whatever The Outcome Of Brexit,2019-07-23 07:25:00-04:00,NVO,positive
933213.0,"Shares of several drug manufacturing companies are trading lower, potentially on continued weakness after the Trump Administration on Thursday rolled back a proposal to eliminate rebates from government drug plans.",2019-07-12 09:53:00-04:00,NVO,negative
933214.0,"Novo Nordisk Reports ESPEROCT For Treatment Of Hemophilia A In Children, Adults Approved In Canada",2019-07-12 07:10:00-04:00,NVO,positive
933215.0,Shares of several drug manufacturing companies are trading lower. The Trump Administration earlier rolled back a proposal to eliminate rebates from government drug plans and commented on continued efforts to lower drug prices.,2019-07-11 10:36:00-04:00,NVO,negative
933216.0,The Week Ahead In Biotech: Pending Clinical Readouts In Focus,2019-06-29 08:25:00-04:00,NVO,neutral
933217.0,Novo Nordisk shares are trading lower after Deutsche Bank downgraded the stock from Buy to Hold.,2019-06-20 13:50:00-04:00,NVO,neutral
933218.0,Novo Nordisk Today Announced That European Commission Has Granted Marketing Authorisation For ESPEROCT,2019-06-20 12:51:00-04:00,NVO,positive
933219.0,"Benzinga's Top Upgrades, Downgrades For June 20, 2019",2019-06-20 09:10:00-04:00,NVO,positive
933220.0,Deutsche Bank Downgrades Novo Nordisk to Hold,2019-06-20 06:47:00-04:00,NVO,neutral
933221.0,"The Daily Biotech Pulse: PhaseBio Pumped Up, Eiger Exults On Breakthrough Therapy Designation, Biohaven Slips On Stock Sale",2019-06-18 07:31:00-04:00,NVO,neutral
933222.0,Novo Nordisk Granted FDA Approval For Victoza,2019-06-17 15:28:00-04:00,NVO,positive
933223.0,Novo Nordisk's Oral Semaglutide Diabetes Drug Shows No Greater Risk Of Heart Problems And Death Than Placebo; Oral Semaglutide Demonstrates Non-Inferiority To Placebo In Type 2 Diabetes Patients At High Risk Of Heart Problems,2019-06-11 14:46:00-04:00,NVO,negative
933224.0,"Benzinga's Top Upgrades, Downgrades For June 11, 2019",2019-06-11 09:19:00-04:00,NVO,positive
933225.0,Barclays Upgrades Novo Nordisk to Equal-Weight,2019-06-11 06:46:00-04:00,NVO,neutral
933226.0,Novo Nordisk shares are trading higher after competitor Eli Lilly announced disappointing diabetes treatment results.,2019-06-10 09:56:00-04:00,NVO,negative
933227.0,"Novo Nordisk Announces That New Data From Its Diabetes Portfolio Will Be Presented At The Upcoming 79th Annual Scientific Sessions Of The American Diabetes Association In San Francisco, California From June 7-11, 2019",2019-05-22 10:44:00-04:00,NVO,neutral
933228.0,Shares of several healthcare companies are trading lower in sympathy with the overall market. The S&P 500 is trading lower 1%,2019-05-10 13:09:00-04:00,NVO,positive
933229.0,"The Daily Biotech Pulse: Obseva Reports Positive Endometriosis Drug Trial, Assembly Biosciences Execs Depart, Coherus Settles With Amgen",2019-05-03 07:49:00-04:00,NVO,positive
933230.0,Novo Nordisk Reaffirms FY 2019 Guidance,2019-05-03 04:31:00-04:00,NVO,neutral
933231.0,Novo Nordisk Q1 Sales 29.3B DKK Beats 29.1B Est,2019-05-03 04:29:00-04:00,NVO,neutral
933232.0,Credit Suisse Upgrades Novo Nordisk A/S Common Stock to Outperform,2019-04-29 08:57:00-04:00,NVO,positive
933233.0,Novo Nordisk Announced Victoza Demonstrated Superiority In Reducing Blood Sugar Vs Placebo In Children And Adolescents With Type 2 Diabetes,2019-04-28 18:26:00-04:00,NVO,positive
933234.0,Novo Nordisk Reports Received Positive Opinion From European Regulatory Authorities For Esperoct For Treatment Of Hemophilia A,2019-04-26 10:50:00-04:00,NVO,positive
933235.0,"Shares of several healthcare stocks are trading higher in a potential rebound from last week's selloff. In an upgrade of HCA Healthcare, Raymond James analysts noted the selloff was 'based on legislation that has almost no chance of passing'",2019-04-23 11:52:00-04:00,NVO,positive
933236.0,"Gilead Sciences, Novo Nordisk Announce Intent to Initiate a Clinical Collaboration in NASH",2019-04-12 04:22:00-04:00,NVO,neutral
933237.0,FDA Says Announcing A Public Hearing To Discuss Access To Affordable Insulin Products,2019-04-02 09:38:00-04:00,NVO,neutral
933238.0,Novo Nordisk Files For FDA Approval Of Oral Semaglutide For Blood Sugar Control And Cardiovascular Risk Reduction In Adults With Type 2 Diabetes,2019-03-20 10:13:00-04:00,NVO,positive
933239.0,Novo Nordisk Settles U.S. Patent Litigation Case On Victoza With Teva,2019-03-18 07:08:00-04:00,NVO,negative
933240.0,"US Senator Ron Wyden Says Finance Committee Continuing To Investigate How Major Insulin Manufacturers Set, Increase 'Outrageous Price Of Insulin'",2019-03-04 12:28:00-05:00,NVO,negative
933241.0,Novo Nordisk shares are trading lower after Eli Lilly announced it would introduce lower priced insulin.,2019-03-04 06:38:00-05:00,NVO,negative
933242.0,"Novo Nordisk Reports Filing For Label Update For Fiasp To EMA, FDA Seeking Approval For Use In Children, Adolescents",2019-03-01 07:16:00-05:00,NVO,positive
933243.0,"US Senate Finance Committee Launches Bipartisan Investigation Into Rising Insulin Prices; Sends Letters To Eli Lilly, Novo Nordisk And Sanofi",2019-02-22 15:57:00-05:00,NVO,neutral
933244.0,"UPDATE: Abbott, Novo Nordisk Partnership Will 'enable insulin data to be shared between Novo Nordisk connected insulin pens and digital health tools compatible(i) with FreeStyle Libre portfolio of products'",2019-02-20 09:05:00-05:00,NVO,positive
933245.0,"Abbott, Novo Nordisk Report Partnership To Provide Integrated Digital Solution to People with Diabetes Using Insulin",2019-02-20 09:05:00-05:00,NVO,positive
933246.0,"Novo Nordisk Says Biologics License Application For Esperoct For Treatment Of Adults, Children With Hemophilia A Approved",2019-02-19 12:34:00-05:00,NVO,positive
933247.0,"Benzinga's Top Upgrades, Downgrades For February 4, 2019",2019-02-04 09:09:00-05:00,NVO,positive
933248.0,Handelsbanken Downgrades Novo Nordisk to Accumulate from Buy; Lowers Price Target to DKK 363 from DKK 375,2019-02-04 04:40:00-05:00,NVO,negative
933249.0,Attention Biotech Investors: Mark Your Calendar For These February PDUFA Dates,2019-02-01 13:30:00-05:00,NVO,neutral
933250.0,"Novo Nordisk shares are trading higher after the company posted a 6% year-over-year increase in sales within its diabetes/obesity segment and reported a DKK15B buyback, offsetting a Q4 earnings miss.",2019-02-01 10:49:00-05:00,NVO,positive
933251.0,Novo Nordisk Earlier Reported DKK15B Buyback,2019-02-01 09:04:00-05:00,NVO,neutral
933252.0,"Novo Nordisk Earlier Reported Q4 EPS $0.53 Misses $0.61 Estimate, Sales $4.552B Miss $4.74B Estimate",2019-02-01 08:47:00-05:00,NVO,negative
933253.0,35 Stocks Moving In Friday's Pre-Market Session,2019-02-01 08:33:00-05:00,NVO,neutral
933254.0,Novo Nordisk Q4 Sales DKK29.73B vs DKK29.77B Est,2019-02-01 04:57:00-05:00,NVO,neutral
933255.0,Exane BNP Paribas Initiates Coverage On Novo Nordisk with Outperform Rating,2019-01-29 10:04:00-05:00,NVO,neutral
933256.0,Novo Nordisk Reports Its Xultophy Is Now Available In Canada,2019-01-23 08:07:00-05:00,NVO,neutral
933257.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials",2018-12-30 15:27:00-05:00,NVO,neutral
933258.0,6 Valuable Pipeline Drugs With Upcoming Catalysts,2018-12-26 14:22:00-05:00,NVO,positive
933259.0,The Week Ahead In Biotech: Focus Shifts To Year-End Clinical Trial Results,2018-12-23 10:37:00-05:00,NVO,neutral
933260.0,Argenx Co-development Partner Staten Biotechnology Enters into Collaboration with Novo Nordisk to Develop Novel Treatment for Dyslipidaemia,2018-12-17 03:59:00-05:00,NVO,positive
933261.0,Morgan Stanley Initiates Coverage On Novo Nordisk with Equal-Weight Rating,2018-12-14 09:58:00-05:00,NVO,neutral
933262.0,E-therapeutics Announces Research Collaboration Agreement with Novo Nordisk,2018-12-10 03:40:00-05:00,NVO,positive
933263.0,Novo Nordisk Earlier Reported In 6-K That Results From Oral Semaglutide Trial Showed Favorable Safety Profile And 'Significant' Reduction In Cardiovascular Death And All-Cause Mortality In Type 2 Diabetes Patients,2018-11-23 10:12:00-05:00,NVO,positive
933264.0,Novo Nordisk Announces Oral Semaglutide Demonstrates Greater Reductions In Both Hba1c and Body Weight vs Victoza In Japanese Adults With Type 2 Diabetes,2018-11-22 18:28:00-05:00,NVO,positive
933265.0,Novo Nordisk shares are up 2.6% after analysts at JP Morgan upgraded the stock from 'Neutral' to 'Overweight',2018-11-19 13:23:00-05:00,NVO,positive
933266.0,"Benzinga's Top Upgrades, Downgrades For November 19, 2018",2018-11-19 09:14:00-05:00,NVO,positive
933267.0,22 Stocks Moving In Monday's Pre-Market Session,2018-11-19 08:13:00-05:00,NVO,neutral
933268.0,JP Morgan Upgrades Novo Nordisk to Overweight,2018-11-19 06:45:00-05:00,NVO,neutral
933269.0,JP Morgan Upgrades Novo Nordisk to Overweight from Neutral; Raises Price Target to DKK 340 from DKK 290,2018-11-19 04:37:00-05:00,NVO,neutral
933270.0,Embark and Novo Nordisk Collaborate to Discover Novel Therapeutics for Obesity and Metabolic Disease,2018-11-02 04:22:00-04:00,NVO,positive
933271.0,"The Daily Biotech Pulse: AbbVie's Leukemia Drug Trial Meets Endpoint, Denali Strikes Collaboration Deal",2018-11-01 07:30:00-04:00,NVO,negative
933272.0,"Novo Nordisk Sees Workforce Cut by 1,300 Employees Before the End of 2018",2018-11-01 04:57:00-04:00,NVO,negative
933273.0,"Earnings Scheduled For November 1, 2018",2018-11-01 04:15:00-04:00,NVO,neutral
933274.0,Why AEterna Zentaris Shares Surged On Novo Nordisk-Strongbridge Biopharma Deal,2018-10-31 16:13:00-04:00,NVO,positive
933275.0,Q3 Earnings Preview For Novo Nordisk,2018-10-31 14:56:00-04:00,NVO,neutral
933276.0,"Aeterna Zentaris Shares Up 25% Following Deal Between Novo Nordisk, Strongbridge For Rights To MACRILEN; Aeterna Zentaris Receives 15-18% Royalties From Sales Of MACRILEN In US, Canada",2018-10-31 09:36:00-04:00,NVO,positive
933277.0,UPDATE: Novo Nordisk Will Leverage And Fund Stonebridge's Rare Endocrine Commercial Field Organization For MACRILEN For Up To Three Years,2018-10-31 08:49:00-04:00,NVO,neutral
933278.0,UPDATE: Strongbridge Biopharma To Receive Upfront Payment Of $145M And Tiered Royalties Related To Sales Of MACRILEN Through 2027; Novo Nordisk To Purchase 5.2M Ordinary Shares Of Stonebridge At $7/Share,2018-10-31 08:47:00-04:00,NVO,positive
933280.0,"Novo Nordisk Issues Release Highlighting Its Oral Semaglutide Showed Statistically Significant Reductions In HbA1c, Body Weight In People With Long-Duration Type-2 Diabetes Treated With Insulin",2018-10-26 08:55:00-04:00,NVO,positive
933281.0,"Anthem, HealthCore And Novo Nordisk Launch Study To Understand Effectiveness Of New Type 2 Diabetes Drug, Ozempic",2018-10-17 09:07:00-04:00,NVO,neutral
933282.0,"Sanofi, Novo Nordisk, Lilly Shares Unaffected Amid Report State Of Minnesota Filed Suit Accusing Insulin Manufacturers Of Deceptive Drug Pricing Practices",2018-10-16 15:06:00-04:00,NVO,positive
933283.0,"The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results And IPOs",2018-10-14 13:21:00-04:00,NVO,neutral
933284.0,"Novo Nordisk Says Fiasp Is Effective at Controlling Blood Sugar Levels in Children and Adolescents Living With Type 1 Diabetes, When Compared to Conventional Insulin Aspart",2018-10-12 06:13:00-04:00,NVO,positive
933285.0,"Stocks Which Set New 52-Week Low Yesterday, October 10th",2018-10-11 09:11:00-04:00,NVO,negative
933286.0,"Stocks Which Set New 52-Week Low Yesterday, October 9th",2018-10-10 11:01:00-04:00,NVO,negative
933287.0,"Benzinga's Top Upgrades, Downgrades For October 8, 2018",2018-10-08 09:12:00-04:00,NVO,positive
933288.0,32 Stocks Moving In Monday's Pre-Market Session,2018-10-08 08:03:00-04:00,NVO,neutral
933289.0,"The Week Ahead In Biotech: Conferences, Clinical Trial Results And IPOs",2018-10-08 07:30:00-04:00,NVO,neutral
933290.0,Bank of America Downgrades Novo Nordisk to Neutral,2018-10-08 06:58:00-04:00,NVO,neutral
933291.0,Novo Nordisk shares are down 7.4% after Eli Lilly earlier reported positive trial results in its diabetes candidates; Novo Nordisk is seen as a competitor in the diabetes space and fell on the news.,2018-10-04 09:23:00-04:00,NVO,positive
933292.0,26 Stocks Moving In Thursday's Pre-Market Session,2018-10-04 07:58:00-04:00,NVO,neutral
933293.0,"Asterias Biotherapeutics Announces an IP License Agreement with an Affiliate of Novo Nordisk, Asterias to Recieve $2M Upfront",2018-10-01 07:09:00-04:00,NVO,positive
933294.0,Novo Nordisk to Establish California Manufacturing Site for Stem Cell-based Therapies,2018-10-01 05:02:00-04:00,NVO,neutral
933295.0,Novo Nordisk Announces First Global Launch Of Connected Insulin Pens,2018-10-01 05:00:00-04:00,NVO,neutral
933296.0,Roche Signs Collaboration Agreement woth Novo Nordisk to Expand Access to Therapy Information by Integrating Insulin Data From Connected Pens to Its Open Ecosystem,2018-10-01 04:49:00-04:00,NVO,positive
933297.0,Novo Nordisk Announces New Phase 2 Data for Somapacitan Demonstrate Its Potential as an Efficacious Once-weekly Treatment for Childhood Growth Hormone Deficiency,2018-09-28 04:22:00-04:00,NVO,positive
933298.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results And IPOs",2018-09-23 16:10:00-04:00,NVO,neutral
933299.0,Novo Nordisk Option Alert: Oct 19 $49 Calls at the Ask: 1919 @ $0.451 vs 2554 OI; Earnings 10/31 Before Open [est] Ref=$47.68,2018-09-21 12:22:00-04:00,NVO,positive
933300.0,"Novo Nordisk Says Oral Semaglutide Showed Greater Reductions In HbA1c, Body Weight, Comparable Number Of Adverse Events vs Dulaglutide",2018-09-20 08:28:00-04:00,NVO,positive
933301.0,"Novo Nordisk Announces Plans to Cut 400 R&D Jobs in Denmark, China; To Establish New Business Development Unit in Cambridge, MA",2018-09-18 04:42:00-04:00,NVO,negative
933302.0,"The Week Ahead In Biotech (Sept. 16-22): Conferences, PDUFA Dates, Clinical Trial Results And IPOs",2018-09-16 14:22:00-04:00,NVO,neutral
933303.0,"The Week Ahead In Biotech: Conferences, Clinical Trial Results, Earnings And IPOs",2018-09-09 16:46:00-04:00,NVO,neutral
933304.0,"Ossianix, Novo Nordisk Report Signing Of Research, Option Deal On Blood Brain Barrier Delivery Technology For Proteins In Diabetes, Other Metabolic Diseases",2018-09-04 09:35:00-04:00,NVO,negative
933305.0,"Evotec, Novo Nordisk Form Strategic Research Alliance in Diabetes and Obesity; Financial Details Not Disclosed",2018-08-22 04:21:00-04:00,NVO,neutral
933306.0,Novo Nordisk Acquires Ziylo; Deal Price Could Exceed $800M,2018-08-17 04:17:00-04:00,NVO,neutral
933307.0,85 Biggest Movers From Yesterday,2018-08-09 05:15:00-04:00,NVO,neutral
933308.0,68 Stocks Moving In Wednesday's Mid-Day Session,2018-08-08 12:30:00-04:00,NVO,neutral
933309.0,40 Stocks Moving In Wednesday's Pre-Market Session,2018-08-08 08:08:00-04:00,NVO,neutral
933310.0,"Earnings Scheduled For August 8, 2018",2018-08-08 06:03:00-04:00,NVO,neutral
933311.0,Novo Nordisk Shares Fall 4.3% in Premarket; Co Reported Operating Profit Down 8% in First 6 Months of 2018,2018-08-08 04:26:00-04:00,NVO,positive
933312.0,A Look At Biotech In 2018 And The Biggest Catalysts Coming Up In The Second Half Of The Year,2018-07-05 12:25:00-04:00,NVO,neutral
933313.0,The Week Ahead In Biotech: Delayed Clinical Trial Releases In Focus,2018-06-30 17:32:00-04:00,NVO,negative
933314.0,"Novo Nordisk Announces Oral Semaglutide Shows Superior Reductions in HbA1c and Weight vs Sitagliptin in Long-term Safety and Efficacy Trial, PIONEER 3",2018-06-28 04:16:00-04:00,NVO,positive
933315.0,Novo Nordisk Says Tresiba Showed Improved Blood Sugar Control Versus Insulin,2018-06-25 08:17:00-04:00,NVO,positive
933316.0,Novo Nordisk Announces Tresiba Demonstrated Significantly Improved Blood Sugar Control and Lower Rates of Hypoglycemia Versus Insulin Toujeo in Real-world Evidence Study at #ADA2018,2018-06-23 18:57:00-04:00,NVO,positive
933317.0,"Novo Nordisk Oral Semaglutide Shows Statistically Significantly Greater Reductions In HbA1c And Weight Compared To Victoza And Sitagliptin In PIONEER 4 
And 7 Trials",2018-06-20 15:29:00-04:00,NVO,positive
933318.0,Novo Nordisk Option Alert: Jul 20 $45 Calls at the Ask: 726 @ $1.25 vs 1790 OI; Earnings 8/8 Before Open [est] Ref=$44.86,2018-06-20 14:59:00-04:00,NVO,positive
933319.0,"Kallyope, Novo Nordisk Report Research Collaboration, Option Agreement To Discover Novel Peptide Therapeutics To Treat Obesity, Diabetes",2018-06-19 06:08:00-04:00,NVO,positive
933320.0,20 Stocks Moving In Friday's Pre-Market Session,2018-06-08 08:09:00-04:00,NVO,neutral
933321.0,"Novo Nordisk Shares Volatile At Close; Co. Considering Laying Off Up To 3K Employees, Dropping Long-Term Financial Targets, Cites Challenging US Market",2018-06-07 16:01:00-04:00,NVO,positive
933322.0,Novo Nordisk Says Trial Achieved Primary Objective  Demonstrating Statistically Significant And Superior Improvement In HBA1C With Oral Semaglutide vs Empagliflozin At 26 Weeks,2018-05-29 12:28:00-04:00,NVO,positive
933323.0,Novo Nordisk Says Oral Semaglutide Shows Superior Improvement In HBA1C vs Empagliflozin In Pioneer 2 Trial,2018-05-29 12:26:00-04:00,NVO,positive
933324.0,Novo Nordisk Announces Real-world Evidence Shows Clinically Meaningful Weight Loss in People Receiving Saxenda,2018-05-24 04:45:00-04:00,NVO,neutral
933325.0,Epigen Biosciences to License its LPA1 Receptor Small Molecule Program to Novo Nordisk for up to $200M,2018-05-23 18:27:00-04:00,NVO,neutral
933326.0,Novo Nordisk Reports New Head-To-Head Pharmacokinetic Study Adults With Hemophilia B Who Received Single Dose Of Rebinyn Achieved High Factor IX Activity For Longer Than Those Treated With rFIXFc,2018-05-21 16:04:00-04:00,NVO,neutral
933327.0,"BioLamina, Novo Nordisk Partner to Advance Stem Cell Based Therapies for Three Common Medical Conditions",2018-05-16 04:27:00-04:00,NVO,neutral
933328.0,Novo Nordisk Reports Q1 Operating Profit DKK12.45B vs DKK11.57B Est,2018-05-02 04:59:00-04:00,NVO,positive
933329.0,Novo Nordisk's Xultophy Approved In Canada For The Treatment Of Adults With Type 2 Diabetes,2018-04-18 15:08:00-04:00,NVO,positive
933330.0,BMO's Bearish Stance On Eli Lilly Comes To An End,2018-04-13 11:00:00-04:00,NVO,neutral
933331.0,"Novo Nordisk, Epidestiny Report Novo Obtained Exclusive Global License To Sickle Cell Disease Programme, EPI01",2018-04-05 08:02:00-04:00,NVO,positive
933332.0,Novo Nordisk Announces FDA Approves Inclusion of Data on Cardiovascular Outcomes and Severe Hypoglycaemia in the Tresiba,2018-03-26 09:45:00-04:00,NVO,neutral
933333.0,Novo Nordisk Elects Helge Lund As New Chairman,2018-03-22 10:28:00-04:00,NVO,neutral
933334.0,Hearing Novo Nordisk Phase 2 Data Presented On Semaglutide Injection Showed Significant Weight Loss In Adults With Obesity,2018-03-20 12:07:00-04:00,NVO,negative
933335.0,UPDATE: Novo Nordisk Says Adults Treated Prophylactically With N8-GP Every 4 Days Experienced Median Bleeding Rate Of 1.3 Episodes vs 30.9 Episodes For People Treated On Demand,2018-02-27 10:17:00-05:00,NVO,negative
933336.0,"Novo Nordisk Filed For Regulatory Approval Of Long-Acting Factor N8-GP In US, EU For Treatment Of Hemophilia A",2018-02-27 10:15:00-05:00,NVO,positive
933337.0,"Pharma Stock Roundup: AstraZeneca, Merck, AbbVie And More",2018-02-23 11:26:00-05:00,NVO,neutral
933338.0,30 Stocks Moving In Thursday's Pre-Market Session,2018-02-22 07:54:00-05:00,NVO,neutral
933339.0,Novo Nordisk's Ozempic Approved in EU for Treatment of Type 2 Diabetes,2018-02-09 06:38:00-05:00,NVO,positive
933340.0,44 Biggest Movers From Yesterday,2018-02-02 04:43:00-05:00,NVO,neutral
933341.0,38 Stocks Moving In Thursday's Mid-Day Session,2018-02-01 12:25:00-05:00,NVO,neutral
933342.0,31 Stocks Moving In Thursday's Pre-Market Session,2018-02-01 08:01:00-05:00,NVO,neutral
933343.0,"Earnings Scheduled For February 1, 2018",2018-02-01 04:39:00-05:00,NVO,neutral
933344.0,Novo Nordisk Shares Fall 5% in Premarket Following Weaker than Expected Q4 Results,2018-02-01 04:37:00-05:00,NVO,negative
933345.0,Sanofi On A Buyout Spree This Month: Announces Ablynx Acquisition For $4.8 Billion,2018-01-30 10:45:00-05:00,NVO,neutral
933346.0,Pharma M&A Picks Up Momentum,2018-01-23 13:56:00-05:00,NVO,neutral
933347.0,Biotech M&A Off To A Strong Start In 2018: More Deals To Follow?,2018-01-23 10:58:00-05:00,NVO,positive
933348.0,Ablynx 10.2% Shareholder Van Herk Investments Says Novo Nordisk Offer Undervalues Co -Reuters,2018-01-18 04:18:00-05:00,NVO,neutral
933349.0,"Eli Lilly's Risks Could Be Underappreciated, Goldman Sachs Says In Downgrade",2018-01-16 12:06:00-05:00,NVO,negative
933350.0,Novo Nordisk Confirms Bid For Ablynx But Faces Rejection,2018-01-09 11:31:00-05:00,NVO,negative
933351.0,Novo Nordisk Reports Health Canada Approved Ozempic To Improve Glycemic Control In Adults With Type 2 Diabetes Mellitus,2018-01-09 08:14:00-05:00,NVO,positive
933352.0,"Ablynx Shares Up 44% Mon. Following Earlier News Co. 'Strongly Believes' €28/Share Offer From Novo Nordisk 'Fundamentally Undervalues The Co., Future Prospects'",2018-01-08 12:00:00-05:00,NVO,positive
933353.0,A Peek Into The Markets: U.S. Stock Futures Mostly Flat Ahead Of Fed Speakers,2018-01-08 07:32:00-05:00,NVO,neutral
933354.0,"Ablynx NV Says Offer By Novo Nordisk To Acquire Co. Fundamentally Undervalues The Co. And Its Future Prospects, Believes The Proposed Consideration And A Complex Instrument Like A CVR Doesn't Constitute A Basis For Further Discussions At This Time",2018-01-08 07:29:00-05:00,NVO,positive
933355.0,Novo Nordisk Proposed to Buy Ablynx for up to €30.50/Share in Cash,2018-01-08 06:50:00-05:00,NVO,neutral
933356.0,Orexigen Struggles As Contrave Commercialization Costs Rise,2018-01-05 10:54:00-05:00,NVO,negative
933357.0,"The Market In 5 Minutes: Apple Issues Apology, Softbank & Uber, The Year In Cryptos",2017-12-29 09:53:00-05:00,NVO,positive
933358.0,"Benzinga's Top Upgrades, Downgrades For December 29, 2017",2017-12-29 08:55:00-05:00,NVO,positive
933359.0,JP Morgan Upgrades Novo Nordisk to Neutral,2017-12-29 06:39:00-05:00,NVO,positive
933360.0,The Companies That Led 2017's Biotech Rally,2017-12-22 09:50:00-05:00,NVO,neutral
933361.0,Novo Nordisk Option Alert: Jun 15 $60 Calls Sweep (2) at the Bid: 939 @ $1.301 vs 113 OI; Ref=$53.2,2017-12-18 11:17:00-05:00,NVO,positive
933362.0,Novo Nordisk Reports CHMP Adopted Position Opinion For Ozempic For Treatment Of Adults With Type 2 Diabetes Mellitus,2017-12-15 07:14:00-05:00,NVO,neutral
933363.0,"Forbes Biotech Reporter Matthew Herper Tweets: Interesting #ASH17: $SHPG up slightly, $NVO down just .5%; nothing on $BIVV. These are the companies that could be hurt by Hemlibra and hemophilia gene therapy.",2017-12-11 07:55:00-05:00,NVO,negative
933364.0,"Bank of America Upgrades Novo Nordisk, Says High Visibility Growth Offered By GLP-1 Makes Franchise Increasingly Attractive; Could See Share Price Upside With Phase 3 Data In Oral semaglutide",2017-12-06 09:53:00-05:00,NVO,positive
933365.0,Bank of America Upgrades Novo Nordisk to Buy,2017-12-06 09:50:00-05:00,NVO,neutral
933366.0,"Benzinga's Top Upgrades, Downgrades For December 6, 2017",2017-12-06 08:56:00-05:00,NVO,positive
933367.0,Bank of America Merrill Lynch Upgrades Novo Nordisk to Buy from Neutral -Reuters,2017-12-06 04:42:00-05:00,NVO,neutral
933368.0,Novo Nordisk Shares Spike As Co. Receives FDA Approval For Semaglutide,2017-12-05 12:52:00-05:00,NVO,positive
933369.0,Novo Nordisk Reports Xultophy Shown to be Better Option than Basal-Bolus Insulin Therapy to Manage Type 2 Diabetes by Participants in Dual VII Clinical Trial,2017-12-05 04:31:00-05:00,NVO,positive
933370.0,"REMINDER: Tuesday Is Estimated FDA PDUFA Date For: Johnson & Johnson for Rilpivirine and In Partnership with GlaxoSmithKline For Dolutegravir, and Novo Nordisk for Semaglutide",2017-12-04 15:49:00-05:00,NVO,neutral
933371.0,"The Week Ahead For December 4: The Biggest Catalysts, Conferences, And Investor Events",2017-12-04 11:23:00-05:00,NVO,neutral
933372.0,Report Published in Journal of Medical Economics Shows Novo Nordisk's Xultophy Offers Greater Weight Reductions than Iglarlixi,2017-12-04 04:57:00-05:00,NVO,positive
933373.0,"The Market In 5 Minutes: Tax Bill, Bitcoin, 'Today' Show, And More",2017-12-01 09:15:00-05:00,NVO,neutral
933374.0,"Benzinga's Top Upgrades, Downgrades For December 1, 2017",2017-12-01 09:11:00-05:00,NVO,positive
933375.0,Morgan Stanley Upgrades Novo Nordisk A/S Common Stock to Overweight,2017-12-01 06:15:00-05:00,NVO,negative
933376.0,Morgan Stanley Upgrades Novo Nordisk to Overweight from Equal Weight -Reuters,2017-12-01 04:41:00-05:00,NVO,negative
933377.0,Attention Biotech Investors: Mark Your Calendar For These December PDUFA Dates,2017-11-30 08:34:00-05:00,NVO,neutral
933378.0,Novo Nordisk Announces Health Canada Approval For Update To Victoza,2017-11-21 08:05:00-05:00,NVO,positive
933379.0,Adam Feuerstein Tweets: $NVO sales of women's hormone therapies (including Vagifem) -54% this year due to generic competition. This is $TXMD future.,2017-11-06 10:08:00-05:00,NVO,neutral
933380.0,Novo Nordisk CEO Says Still Looking to Make Bolt-On Biopharma Acquisitions -Reuters,2017-11-01 08:17:00-04:00,NVO,neutral
933381.0,"Earnings Scheduled For November 1, 2017",2017-11-01 04:33:00-04:00,NVO,neutral
933382.0,Novo Nordisk CEO Says Legislation in Some U.S. States to Increase Pricing Transparency May Make It Difficult to Conduct Business -Reuters,2017-11-01 04:11:00-04:00,NVO,negative
933383.0,Novo Nordisk Press Release Confirms Positive FDA AdCom Vote In Favor Of Semaglutide Approval,2017-10-18 17:36:00-04:00,NVO,positive
933384.0,FDA Panel Shows Support Of FDA Approval For Novo Nordisk's Semaglutide,2017-10-18 16:27:00-04:00,NVO,positive
933385.0,SHB Upgrades Novo Nordisk to Buy from Accumulate; Raises PT to DKK 357 from DKK 326,2017-10-18 05:01:00-04:00,NVO,neutral
933386.0,Novo Nordisk's Semaglutide Was Effective and Not Associated with Risk According to the FDA,2017-10-16 08:00:00-04:00,NVO,positive
933387.0,Novo Nordisk Reports Received FDA Approval For Fiasp,2017-09-29 11:04:00-04:00,NVO,positive
933388.0,Novo Nordisk's New-Generation Basal Insulin Tresiba Approved in China,2017-09-27 04:54:00-04:00,NVO,positive
933389.0,"With New CEO In Place, Focus For Teva Pharma Turns To 'Execution'",2017-09-12 10:11:00-04:00,NVO,neutral
933390.0,"A Look At Kare Schultz, The New CEO In Charge Of Teva",2017-09-11 15:59:00-04:00,NVO,neutral
933391.0,"Benzinga's Top Upgrades, Downgrades For September 6, 2017",2017-09-06 09:27:00-04:00,NVO,positive
933392.0,The Market In 5 Minutes,2017-09-06 08:58:00-04:00,NVO,neutral
933393.0,Bank of America Upgrades Novo Nordisk A/S Common Stock to Neutral,2017-09-06 06:47:00-04:00,NVO,neutral
933394.0,"Novo Nordisk Announces Conclusion Of Federal Investigation Into Marketing Practices, Co. Will Pay $46.5M To Federal Govt. And States, $12.5M For FDA Related Complaint",2017-09-05 17:13:00-04:00,NVO,negative
933395.0,"UPDATE: Bloomberg Issues Correction On Earlier Headline, U.S. To Seek $12.2 Million, Not Billion, From Novo Nordisk",2017-09-05 15:50:00-04:00,NVO,neutral
933396.0,Hearing The U.S. Seeks $12.15M From Novo Nordisk In Fraud Suit,2017-09-05 15:39:00-04:00,NVO,negative
933397.0,Attention Biotech Investors: September Ushers In Another Slew Of PDUFA Catalysts,2017-09-01 14:03:00-04:00,NVO,neutral
933398.0,Novo Nordisk Issues Release Confirming Victoza Approved In US As Type-2 Diabetes Treatment Indicated To Reduce The Risk Of 3 Major Adverse Cardiovascular Events,2017-08-25 12:21:00-04:00,NVO,negative
933399.0,Novo Nordisk Reports Positive Semaglutide Trial Results,2017-08-16 14:09:00-04:00,NVO,positive
933400.0,Shares of Lilly Fall on Positive Novo Nordisk SUSTAIN 7 Trial Results,2017-08-16 14:08:00-04:00,NVO,positive
933401.0,Novo Nordisk Reports Operating Profit Rose by 8% in First Six Months of 2017; Shares Up 5.42% @$43.38 in Premarket,2017-08-09 04:37:00-04:00,NVO,positive
933402.0,August PDUFA Dates: Biotech Investors Stay Tuned To A Month Of Plenty,2017-08-01 09:20:00-04:00,NVO,neutral
933403.0,Watch These 8 Huge Put Purchases In Wednesday Trade,2017-07-26 04:18:00-04:00,NVO,positive
933404.0,Benzinga's Option Alert Recap From July 25,2017-07-25 16:00:00-04:00,NVO,positive
933405.0,Novo Nordisk Option Alert: Aug 18 $41 Puts Sweep (28) at the Ask: 746 @ $1.25 vs 75 OI; Ref=$42.09,2017-07-25 13:57:00-04:00,NVO,positive
933406.0,"Novo Nordisk Reports Recall Of Cartridge Holders For Certain NovoPen Echo Devices, Cites Potential Health Risks",2017-07-05 15:32:00-04:00,NVO,neutral
933407.0,Benzinga's Option Alert Recap From June 30,2017-06-30 16:10:00-04:00,NVO,positive
933408.0,Option Alert: Novo Nordisk Sep 41.0 Calls Sweep: 615 @  ASK  $3.20: 615 traded vs 63 OI:  Earnings 8/9 Before Open  $43.01 Ref,2017-06-30 10:33:00-04:00,NVO,positive
933410.0,"Novo Nordisk Reports Positive Patient Response In Semaglutide Phase 2 Trial, Expects Phase 3 Program To Begin In 2018",2017-06-23 10:50:00-04:00,NVO,positive
933412.0,Novo Nordisk Expects Feedback From EMA on Victoza Application Shortly,2017-06-22 14:21:00-04:00,NVO,neutral
933415.0,Novo Nordisk Receives 17-2 Vote from FDA Advisory Committee that Victoza Provides Substantial Evidence of Cardiovascular Risk Reduction in Patients with Tpe 2 Diabetes,2017-06-21 05:06:00-04:00,NVO,negative
933417.0,Novo Nordisk +2.8% Premarket @$45.15 on Light Trading; Co Announced Submitted EU Application for Tresiba Including Data from Devote Trial,2017-06-14 07:13:00-04:00,NVO,positive
933418.0,Novo Nordisk Submits EU Application for Tresiba,2017-06-14 07:08:00-04:00,NVO,neutral
933419.0,"Novo Nordisk Announces Tresiba Showed No Increased Risk Of Major Cardiovascular Events, Significant Reduction In Rates Of Severe Hypoglycaemia vs Insulin Glargine",2017-06-12 17:24:00-04:00,NVO,negative
933420.0,Companies Holding Analyst/Investor Days Today Include Novo-Nordisk and Advaxis,2017-06-12 08:32:00-04:00,NVO,neutral
933421.0,"Novo Nordisk Reports Data Show Switching to Tresiba Provides Significant Reductions in Blood Glucose, Lower Rates of Hypoglycaemia in Real-world Setting",2017-06-11 15:42:00-04:00,NVO,negative
933422.0,Novo Nodisk Reports European Commission Has Granted Marketing Authorization For Refixia,2017-06-06 11:12:00-04:00,NVO,positive
933423.0,22 Stocks Moving In Friday's Pre-Market Session,2017-06-02 08:16:00-04:00,NVO,neutral
933424.0,Novo Nordisk Reports Received FDA Approval of REBINYN,2017-05-31 14:54:00-04:00,NVO,positive
933425.0,Novo Nordisk Submits Supplemental Application to FDA for Including Data from Devote Trial in Tresiba Label,2017-05-27 15:41:00-04:00,NVO,positive
933426.0,"Q1 Seasonality In The Pharma/Biotech Space: What It Is, Why It Happens And Who Is Affected",2017-05-24 11:02:00-04:00,NVO,negative
933427.0,Will TherapeuticsMD's Yuvvexy Pass The FDA Muster?,2017-05-07 14:29:00-04:00,NVO,neutral
933428.0,20 Biggest Mid-Day Gainers For Wednesday,2017-05-03 12:37:00-04:00,NVO,neutral
933429.0,Novo Nordisk Launches Xultophy Insulin In The United States,2017-05-03 10:15:00-04:00,NVO,positive
933430.0,25 Stocks Moving In Wednesday's Pre-Market Session,2017-05-03 08:05:00-04:00,NVO,neutral
933431.0,Novo Nordisk Announced Increased Operating Profit By 10% in First Three Months of 2017; Shares up 6.6% @$41.50 Premarket,2017-05-03 04:54:00-04:00,NVO,positive
933432.0,"Business Insider Reporting, 'Novo Nordisk has been accused of engaging in a 'white coat marketing scheme' to sell diabetes drugs'",2017-04-28 14:53:00-04:00,NVO,positive
933433.0,Mark Your Calendar For These Days In May To Play The Volatility Around FDA Decision Dates,2017-04-25 13:44:00-04:00,NVO,positive
933434.0,Novo's Once-weekly Semaglutide Shows Consistent Bloodglucose Reductions; Results Presented at Endo 2017,2017-04-03 06:15:00-04:00,NVO,neutral
933435.0,"FDA Briefing Document for Novo Nordisk BLA 125611 Coagulation Factor IX (Recombinant), GlycoPEGylated N9-GP",2017-03-31 10:12:00-04:00,NVO,neutral
933436.0,"Novo Nordisk Announces FDA Posts Briefing Materials Prior to Advisory Committee Meeting for Nonacog Beta Pegol, a Long-acting Factor IX for Treatment of Haemophilia B",2017-03-31 10:10:00-04:00,NVO,neutral
933437.0,Novo Nordisk Reports Resubmission of NDA for Fast-Acting Insulin Aspart in US,2017-03-29 10:54:00-04:00,NVO,neutral
933438.0,Novo Nordisk Launches Fiasp in Canada for Treatment of Diabetes in Adults,2017-03-27 04:16:00-04:00,NVO,neutral
933439.0,Novo Nordisk Receives Positive Opinion From European Regulatory Authorities For Refixia,2017-03-24 08:35:00-04:00,NVO,positive
933440.0,"Novo Nordisk Says CHMP Provides Positive Opinion For EU Label Update For Tresiba Based On Data From Switch Trials, Demonstrated Clinically Relevant Reductions In Hypoglycaemia Compared With Insulin Glargine U100",2017-03-24 07:32:00-04:00,NVO,positive
933441.0,Novo Nordisk CEO Says Looking At External Innovation But Won't Turn Co. Into 'Big M&A Machine',2017-03-23 09:49:00-04:00,NVO,positive
933442.0,"Companies Holding Annual Shareholder Meetings Today Include: KalVista Pharma, Novo Nordisk, Verifone, Stellar Biotech, & Ciena",2017-03-23 09:05:00-04:00,NVO,neutral
933443.0,CVS Health Launches Reduced Rx Savings Program With Novo Nordisk Participating In The Saving Program,2017-03-16 08:24:00-04:00,NVO,neutral
933444.0,"Adam Feuerstein Weighs In On Novo-GBT Rumors, Undue Sarepta Volatility, Unprofitable Business Of Curing Disease",2017-03-10 14:33:00-05:00,NVO,neutral
933445.0,"Feuerstein on Recent Global Blood Therapeutics Rumor: Says 'Kind of Fits in with [Novo's] Strategic' Angling, Says He's Liked GBT for a Long Time Now, Cites Data for Lead Drug in Sickle Cell",2017-03-10 09:06:00-05:00,NVO,positive
933446.0,Wall Street's M&A Chatter From March 9,2017-03-10 06:47:00-05:00,NVO,neutral
933447.0,Biotech Reporter Adam Feuerstein Will Be On Benzinga's PreMarket Prep Friday Morning,2017-03-09 17:14:00-05:00,NVO,neutral
933448.0,Novo Nordisk CEO Says Looking at Deals in Low Billions of Dollars; Declines Comment on GBT Rumor -Reuters,2017-03-09 11:37:00-05:00,NVO,negative
933449.0,Global Blood Therapeutics Spikes to High of $36.28 on Renewed Takeover Chatter Involving Novo Nordisk,2017-03-09 11:36:00-05:00,NVO,neutral
933450.0,Wall Street's M&A Chatter From March 8,2017-03-09 07:26:00-05:00,NVO,neutral
933451.0,EP Vantage Journalist Jacob Plieth Tweets: Hearing rumour that Morgan Stanley might advise $NVO on $GBT deal. Board has authorised $NVO CEO to bid up to $45.,2017-03-08 13:56:00-05:00,NVO,neutral
933452.0,Global Blood Shares Halted on Circuit Breaker Amid Report Novo Nordisk Approached Co.,2017-03-08 10:47:00-05:00,NVO,positive
933453.0,18 Biggest Mid-Day Losers For Thursday,2017-02-02 12:50:00-05:00,NVO,negative
933454.0,22 Stocks Moving In Thursday's Pre-Market Session,2017-02-02 08:19:00-05:00,NVO,neutral
933455.0,Teva Files ANDA With FDA To Seek Generic Version Of Victoza Injection,2017-02-02 08:04:00-05:00,NVO,neutral
933456.0,"Recent Weakness In Eli Lilly, Novo Nordisk, Sanofi Due To New York Times Reporting Drug Makers Accused Of Fixing Drug Prices On Insulin",2017-01-30 14:45:00-05:00,NVO,negative
933457.0,"Novo Nordisk Announces Collaboration With University of Oxford on Type 2 Diabetes, Invests £115M in New Research Centre",2017-01-30 04:32:00-05:00,NVO,neutral
933458.0,Novo Nordisk -3.1% Premarket @$34.55; Class Action Lawsuit Filed Against Co Claiming Inflated Earnings and Forecasts Due to Price Fixing of Insulin Drugs,2017-01-12 04:36:00-05:00,NVO,negative
933459.0,"Bernstein Litowitz Berger & Grossmann LLP Announces Securities Class Action Suit Filed Against Novo Nordisk, Certain of its Senior Executives",2017-01-12 04:23:00-05:00,NVO,positive
933460.0,Novo Nordisk Reports European Commission Has Granted Marketing Authorization For FIASP For Diabetes Treatment In Adults,2017-01-10 08:20:00-05:00,NVO,positive
933461.0,Jim Cramer Shares His Thoughts On Groupon And Novo Nordisk,2016-12-21 06:51:00-05:00,NVO,positive
933462.0,"Novo Nordisk Reports Received FDA Approval of Tresiba for Use in Children, Adolescents with Diabetes",2016-12-19 14:01:00-05:00,NVO,positive
933463.0,Jefferies' 2017 Global Pharma Outlook,2016-12-19 10:56:00-05:00,NVO,neutral
933464.0,A Primer On NASH,2016-12-15 09:47:00-05:00,NVO,neutral
933465.0,Novo Nordisk Shares Spike Higher Following Mid-Day Upgrade from Sell to Buy by UBS,2016-12-06 11:42:00-05:00,NVO,positive
933466.0,"Novo Nordisk Shares Up ~$0.60 Over Last Min, Now Up 1.7% for Session",2016-12-06 11:39:00-05:00,NVO,positive
933467.0,Novo Nordisk Volume Spike,2016-12-06 11:38:00-05:00,NVO,neutral
933468.0,Novo Nordisk Files for Regulatory Approval of Once-Weekly Semaglutide with the FDA for the Treatment of Type 2 Diabetes,2016-12-05 09:43:00-05:00,NVO,positive
933469.0,"Novo Nordisk Files for Regulatory Approval of Once-weekly Semaglutide in US, EU for Treatment of Type 2 Diabetes",2016-12-05 09:38:00-05:00,NVO,positive
933470.0,Novo Nordisk Announces Xultophy Demonstrates Similar Glucose Control With Reduced Risk of Hypoglycaemia and Superior Weight Profile vs Basal-bolus Therapy,2016-12-02 06:07:00-05:00,NVO,positive
933471.0,Novo Nordisk + 4% Preamarket @$33.99; Co Presenting Today at Piper Jaffray Healthcare Conference,2016-11-30 08:40:00-05:00,NVO,neutral
933472.0,UPDATE: Novo Nordisk Says Trial of Tresiba Met Primary Endpoint,2016-11-29 13:05:00-05:00,NVO,neutral
933473.0,"Novo Nordisk Announces Tresiba Showed Safe Cardiovascular Profile, Reduces Risk of Severe Hypoglycaemia vs Insulin Glargine",2016-11-29 13:04:00-05:00,NVO,negative
933474.0,"Novo Nordisk Prices of Xultophy Will be 20 Percent Cheaper Than Tresiba, Victoza Price",2016-11-22 07:21:00-05:00,NVO,neutral
933475.0,Novo Nordisk Reports Received FDA Approval for Xultophy 100/3.6,2016-11-21 16:59:00-05:00,NVO,positive
933476.0,Stocks Hitting 52-Week Lows,2016-11-18 10:20:00-05:00,NVO,negative
933477.0,Novo Nordisk Announces Tresiba Demonstrated Lower Day-to-day and Within-day Variability in Glucose-lowering Effect vs Insulin Glargine U300,2016-11-12 08:16:00-05:00,NVO,negative
933478.0,Hearing Intereconomia Reporting Novartis To Acquire AstraZeneca,2016-11-11 11:48:00-05:00,NVO,neutral
933479.0,Novo Nordisk Receives Positive Opinion From EU Regulatory Authorities For Fiasp For Diabetes Treatment,2016-11-11 07:27:00-05:00,NVO,positive
933480.0,Novo Nordisk Reports Submission of Application in EU for Including Data from Two SWITCH Trials in Tresiba Label,2016-11-10 06:57:00-05:00,NVO,neutral
933481.0,"Senator Bernie Sanders Tweets: People are dying or getting sicker because they can't afford their insulin, just so Eli Lilly and Novo Nordisk can make outrageous profits.",2016-11-01 12:31:00-04:00,NVO,neutral
933482.0,Benzinga's Top Downgrades,2016-10-31 09:28:00-04:00,NVO,positive
933483.0,Citigroup Downgrades Novo Nordisk A/S Common Stock to Neutral,2016-10-31 06:05:00-04:00,NVO,neutral
933484.0,Mid-Afternoon Market Update: Crude Oil Down Over 2%; McKesson Shares Drop On Downbeat Earnings,2016-10-28 15:05:00-04:00,NVO,negative
933485.0,18 Biggest Mid-Day Losers For Friday,2016-10-28 12:55:00-04:00,NVO,negative
933486.0,Mid-Day Market Update: Integer Gains On Earnings Beat; Senomyx Shares Slide,2016-10-28 12:00:00-04:00,NVO,positive
933487.0,"Worst Performing Industries For October 28, 2016",2016-10-28 11:15:00-04:00,NVO,negative
933488.0,Stocks Hitting 52-Week Lows,2016-10-28 10:17:00-04:00,NVO,negative
933489.0,Mid-Morning Market Update: Markets Mostly Higher; Mastercard Beats Q3 Views,2016-10-28 10:02:00-04:00,NVO,neutral
933490.0,Bank of America Downgrades Novo Nordisk A/S Common Stock to Underperform,2016-10-28 09:43:00-04:00,NVO,neutral
933491.0,18 Stocks Moving In Friday's Pre-Market Session,2016-10-28 08:37:00-04:00,NVO,neutral
933492.0,Novo Nordisk Sheds $15 Billion In Market Value Following Warning Of Significant Challenges,2016-10-28 07:55:00-04:00,NVO,positive
933493.0,Novo Nordisk -16% Premarket @$34.42 as Company Provides Cautious Guidance on US Market,2016-10-28 06:47:00-04:00,NVO,negative
933494.0,"Novo Nordisk Says Market Environment in US has become Significantly More Challenging, Negatively Impacting Future Pricing for Company's Products",2016-10-28 06:00:00-04:00,NVO,positive
933495.0,Novo Nordisk Reports Q3 EPS $0.58 vs $0.56 Est; Revenue $4.13B vs $4.12B Est,2016-10-28 05:58:00-04:00,NVO,neutral
933496.0,"Earnings Scheduled For October 28, 2016",2016-10-28 04:02:00-04:00,NVO,neutral
933497.0,"Novo Nordisk Submits Application to FDA, EMA to Include LEADER Data in Victoza Label",2016-10-25 14:33:00-04:00,NVO,neutral
933498.0,Stocks Hitting 52-Week Lows,2016-10-12 10:28:00-04:00,NVO,negative
933499.0,Novo Nordisk Receives CRL from FDA for Faster-acting Insulin Aspart,2016-10-09 08:51:00-04:00,NVO,neutral
933500.0,"Novo Nordisk Announces Plans to Reduce Workforce by ~1,000 Employees; ~50% of Layoffs in Denmark",2016-09-29 04:19:00-04:00,NVO,neutral
933501.0,"vTv Therapeutics Shares Initiated With Buy Rating, $13 Target",2016-09-26 11:46:00-04:00,NVO,positive
933502.0,PiperJaffray Initiates Coverage on Novo-Nordisk at Neutral,2016-09-23 06:46:00-04:00,NVO,neutral
933503.0,NASH Sympathy Plays On Tobira Therapeutics Deal,2016-09-20 14:43:00-04:00,NVO,positive
933504.0,Novo Nordisk Announces Semaglutide Reduced Major Cardiovascular Events By 26% In Adults With Type 2 Diabetes At High Cardiovascular Risk,2016-09-16 06:05:00-04:00,NVO,negative
933505.0,"The Market In 5 Minutes: Huge FDA News, Major Mid-Week M&A",2016-09-14 09:17:00-04:00,NVO,positive
933506.0,Exane BNP Paribas Upgrades Novo-Nordisk to Outperform,2016-09-14 04:58:00-04:00,NVO,neutral
933507.0,12 Biggest  Mid-Day  Gainers For Monday,2016-09-12 12:28:00-04:00,NVO,neutral
933508.0,Benzinga's Top Upgrades,2016-09-12 09:21:00-04:00,NVO,positive
933509.0,Deutsche Bank Upgrades Novo-Nordisk to Buy,2016-09-12 06:01:00-04:00,NVO,neutral
933510.0,"Barron's Picks And Pans: Vodafone, BorgWarner, Novo Nordisk And More",2016-09-11 17:04:00-04:00,NVO,neutral
933511.0,Benzinga's Top Downgrades,2016-09-09 08:49:00-04:00,NVO,positive
933512.0,JP Morgan Downgrades Novo-Nordisk to Neutral,2016-09-09 06:26:00-04:00,NVO,positive
933513.0,"Novo Nordisk Issues Voluntary Recall Of 6 Batches Of Glucagen Hypokit Due To Detached Needles, Estimates 71,215 Pens Being Recalled; Not Aware Of Any Known Adverse Events Resulting From Recall",2016-09-08 14:24:00-04:00,NVO,negative
933514.0,UPDATE: Novo Nordisk CEO Says Questions if it Makes Sense to Produce Fifth-gen Insulin Analogues,2016-09-01 06:02:00-04:00,NVO,neutral
933515.0,Novo Nordisk CEO Says Pricing Environment in US Becoming More Difficult for Pharmaceutical Companies -Reuters,2016-09-01 05:46:00-04:00,NVO,negative
933516.0,Lars Rebien Sørensen to Retire as CEO of Novo Nordisk; Lars Fruergaard Jørgensen Named Successor,2016-09-01 05:19:00-04:00,NVO,positive
933517.0,Benzinga's Top Upgrades,2016-08-31 08:48:00-04:00,NVO,positive
933518.0,HSBC Upgrades Novo-Nordisk to Hold,2016-08-31 06:32:00-04:00,NVO,neutral
933519.0,Stocks Hitting 52-Week Lows,2016-08-12 10:20:00-04:00,NVO,negative
933520.0,12 Biggest Mid-Day Losers For Monday,2016-08-08 13:07:00-04:00,NVO,negative
933521.0,"Worst Performing Industries For August 8, 2016",2016-08-08 11:21:00-04:00,NVO,negative
933522.0,Bank of America Downgrades Novo-Nordisk to Neutral,2016-08-08 07:18:00-04:00,NVO,neutral
933523.0,"Earnings Scheduled For August 5, 2016",2016-08-05 04:02:00-04:00,NVO,neutral
933524.0,"Novo Nordisk +1.9% Premarket @ $56.36; Nordea Markets in Note to Clients, Said Diabetes Treatment Victoza Likely Will Re-enter Medicare Plans at Express Scripts",2016-07-26 09:07:00-04:00,NVO,neutral
933525.0,Novo Nordisk Invests $60M in Expanded Production Plant in Kalundborg,2016-07-04 18:42:00-04:00,NVO,neutral
933526.0,Novo A/S Names Kasim Kutay as New CEO,2016-06-21 04:01:00-04:00,NVO,neutral
933527.0,Novo Nordisk Vol Spike; Gaps Down to Low of $51.33,2016-06-17 10:06:00-04:00,NVO,negative
933528.0,Lesson Learned: Don't Trust Twitter Users With A Multi-Billion-Dollar Secret,2016-06-15 10:46:00-04:00,NVO,negative
933529.0,Jefferies Shares Pharma Stock Catalyst Outlook,2016-06-14 16:33:00-04:00,NVO,positive
933530.0,"Worst Performing Industries For June 14, 2016",2016-06-14 11:36:00-04:00,NVO,negative
933531.0,Novo Nordisk Announces: Faster-Acting Insulin Aspart Showed A Statistically Significant Reduction In Hba1C In Type 1 Diabetes And A Comparable Hba1C Reduction In Type 2 Diabetes Versus Novorapid at ADA,2016-06-13 10:05:00-04:00,NVO,positive
933532.0,"Novo Nordisk Announces Tresiba Demonstrated Significantly Lower Rates of Overall, Nocturnal and Severe Hypoglycaemia vs Insulin Glargine U-100  at the American Diabetes Association 76th Scientific Sessions",2016-06-12 09:12:00-04:00,NVO,negative
933533.0,"Novo Nordisk Says Three-Year Data Show Early Response to Saxenda Resulted In Improvements In Weight Loss, Cardiometabolic Risk Factors -Reuters",2016-06-02 12:14:00-04:00,NVO,negative
933534.0,"Novo Nordisk Shows Three-Year Data Demonstrated Early Response to Saxenda Which Resulted in Improved Weight Loss, Cardiometabolic Risk",2016-06-02 12:13:00-04:00,NVO,negative
933535.0,Novo Nordisk's Ideglira Receives Unanimous 16-0 Vote in Favor of Approval from FDA Advisory Committee,2016-05-25 06:02:00-04:00,NVO,positive
933536.0,Novo Nordisk's Ideglira Receives 16-0 Vote in Favor of Approval from FDA Panel,2016-05-24 17:25:00-04:00,NVO,positive
933537.0,FDA Staff Review of Novo Nordisk Diabetes Drug Showed Inadequate Dosing of Insulin in the Studies Could Have Biased the Estimate of Efficacy in Favor of Combination Product -Reuters,2016-05-20 08:26:00-04:00,NVO,negative
933538.0,Novo Nordisk Files for US Regulatory Approval of Long-Acting Factor IX for Treatment of Haemophilia B,2016-05-16 10:37:00-04:00,NVO,positive
933539.0,"Earnings Scheduled For April 29, 2016",2016-04-29 04:07:00-04:00,NVO,neutral
933540.0,Novo Nordisk +3% Premarket @$56.99 Following Report Semaglutide Significantly Reduces Risk of Major Adverse Cardiovascular Events in the SUSTAIN 6 Trial,2016-04-28 06:46:00-04:00,NVO,negative
933541.0,UPDATE: Novo Nordisk Expects to File Semaglutide for Regulatory Review in US and EU in Q4 of 2016.,2016-04-28 06:28:00-04:00,NVO,neutral
933542.0,Novo Nordisk Report Semaglutide Significantly Reduces Risk of Major Adverse Cardiovascular Events in the SUSTAIN 6 Trial,2016-04-28 06:27:00-04:00,NVO,negative
933543.0,SocGen Picks New Favorites In Big Pharma,2016-04-06 13:44:00-04:00,NVO,positive
933544.0,WHO Says Number of Adults with Diabetes has Quadrupled Since 1980 -AFP,2016-04-06 04:52:00-04:00,NVO,positive
933545.0,Novo Nordisk Says Phase 3A Clinical Trial For Semaglutide Once-Weekly Demonstrated Significantly Improved Glycaemic Control Compared To Placebo In Adults With Type 2 Diabetes,2016-04-02 16:31:00-04:00,NVO,positive
933546.0,Novo Nordisk Reports Victoza Provided Superior HbA1c Reductions in Adults with Type 2 Diabetes Compared to Continued Sitagliptin Treatment,2016-04-02 16:30:00-04:00,NVO,positive
933547.0,Citi Downgrades Novartis Following SAG Investigation,2016-03-29 10:10:00-04:00,NVO,neutral
933548.0,Novo Nordisk Says ‍Victoza Significantly Reduces Risk of Major Adverse Cardiovascular Events in Leader Tria​; Says ‍Safety Profile of Victoza in Leader Was Generally Consistent With Previous Liraglutide Clinical Studies​,2016-03-04 07:11:00-05:00,NVO,negative
933549.0,UPDATE: Novo Nordisk Says ‍Trial Met Primary End-Point by Demonstrating Non-Inferiority in Rate of Severe or Blood Glucose Confirmed Symptomatic Hypoglycemia of Tresiba vs Insulin Glargine,2016-02-23 05:17:00-05:00,NVO,negative
933550.0,NovoNordisk Spikes to High of $50.71 on Volume,2016-02-19 10:57:00-05:00,NVO,neutral
933551.0,Goldman Sachs Upgrades Novo-Nordisk to Conviction Buy,2016-02-15 08:03:00-05:00,NVO,neutral
933552.0,Benzinga's Top Downgrades,2016-02-08 09:38:00-05:00,NVO,positive
933553.0,UBS Downgrades Novo-Nordisk to Sell,2016-02-08 05:40:00-05:00,NVO,neutral
933554.0,"Worst Performing Industries For February 4, 2016",2016-02-04 11:37:00-05:00,NVO,negative
933555.0,Novo Nordisk Lowers Target for Long-Term Operating Profit Growth from 15% to 10%,2016-02-03 05:12:00-05:00,NVO,positive
933556.0,Novo Nordisk Announces Tresiba Showed Significantly Lower Rate of Hypglycaemia vs. Insulin Glargine in Phase 3b Trial,2016-01-29 08:40:00-05:00,NVO,negative
933557.0,"Oddo Securities Upgrades Novo-Nordisk to Buy, Expects European EPS To Grow, Expects Co To Outperform Peers",2016-01-26 08:57:00-05:00,NVO,positive
933558.0,Novo Nordisk Files for Regulatory Approval Of Long-Acting Factor IX in EU for Treatment of Haemophilia B,2016-01-07 05:58:00-05:00,NVO,positive
933559.0,"Early Global News: Obama Meets Bloomberg, Microsoft Supplying Chinese Government With Windows 10, And More",2015-12-17 07:28:00-05:00,NVO,neutral
933560.0,"Novo Nordisk Fourth Phase 3a Trial with Semaglutide in People with Type 2 Diabetes Shows Drug Safe, Well-Tolerated",2015-12-17 04:37:00-05:00,NVO,positive
933561.0,"Novo Nordisk Submits NDA to FDA for Faster-Acting Insulin Aspart for Treatment of Type 1,  2 Diabetes",2015-12-09 04:19:00-05:00,NVO,neutral
933562.0,"Novo Nordisk Files for Regulatory Approval of Faster-Acting Insulin Aspart EU to Treat Type 1, Type 2 Diabetes; Expects to File  NDA With FDA Before Year-End 2015",2015-12-04 04:48:00-05:00,NVO,positive
933563.0,"Wedbush Reiterates Outperform Rating, $6 Target on Xoma Following News Co. Licensed XMetA for Diabetes to Novo Nordisk",2015-12-02 06:59:00-05:00,NVO,neutral
933564.0,"Novo Norsosk Says Tests Show Victoza Provides Greater HBA1C Reduction, Improved Likelihood of Reaching Glycaemic Goals Compared to Sglt-2 Inhibitors -Reuters",2015-12-01 13:11:00-05:00,NVO,positive
933565.0,"Hearing Novo Nordisk Has Said Tests Showing Victoza Demonstrates Greater HBA1C Reduction, Improved Likelihood of Achieving Glycaemic Goals vs. SGLT-2 Inhibitors",2015-12-01 13:10:00-05:00,NVO,positive
933566.0,XOMA Reports Licensing Deal with  Novo Nordisk for XMetA Program in Diabetes,2015-12-01 08:31:00-05:00,NVO,neutral
933567.0,"Ablynx Announces Nanobody Drug Discovery Collaboration, Licence Agreement With Novo Nordisk",2015-11-25 04:23:00-05:00,NVO,positive
933568.0,Novo Nordisk +4% Premarket Following Announcement of Sanofy Diabetes License Agreement With Hanmi,2015-11-05 08:25:00-05:00,NVO,positive
933569.0,"Hearing Novo Nordisk Has Said Data Presented on Saxenda Showed Significant, Sustained Weight Loss Over Three Years vs. Placebo",2015-11-04 12:39:00-05:00,NVO,negative
933570.0,Emisphere Signs License Agreement With Novo Nordisk to Develop Oral Formulations of Four Molecules Targeting Metabolic Indications and Amends GLP-1 Agreement,2015-10-15 08:26:00-04:00,NVO,positive
933571.0,"UPDATE: Tresiba, Ryzodeg Manufactured by Novo Nordisk",2015-09-25 14:51:00-04:00,NVO,neutral
933572.0,FDA Approves Two New Drug Treatments For Diabetes Mellitus,2015-09-25 14:50:00-04:00,NVO,positive
933573.0,Novo Nordisk Spikes Higher,2015-09-25 14:49:00-04:00,NVO,neutral
933574.0,Novo Nordisk Says Second Phase 3A Trial With Semaglutide in People With Type 2 Diabetes Achieved Objective,2015-09-25 04:19:00-04:00,NVO,neutral
933575.0,Novo Nordisk Says Victoza Provides Significantly Greater HbA1c Reduction Than Lixisenatide in New Clinical Trial,2015-09-16 05:44:00-04:00,NVO,positive
933576.0,Novo Nordisk Says New Xultophy Phase 3B Trial Shows Improvements In Patient-Reported Outcomes vs Insulin Glargine -Reuters,2015-09-15 06:10:00-04:00,NVO,positive
933577.0,"Novo Nordisk Says New Data On Saxenda Show Early Response Predicts Improvements In Weight Los, Cardiometabolic Risk Factors -Reuters",2015-09-15 06:10:00-04:00,NVO,positive
933578.0,Novo Nordisk Says New Data Confirm Tresiba U200 Delivers Significantly Lower Rates Of Confirmed Hypoglycaemia vs Insulin Glargine U100 -Reuters,2015-09-15 06:09:00-04:00,NVO,negative
933579.0,"Novo Nordisk Invests $76M in Raw Material Warehouse in Hillerød, Denmark -Reuters",2015-09-03 05:13:00-04:00,NVO,neutral
933580.0,Benzinga's Top Initiations,2015-08-28 09:33:00-04:00,NVO,positive
933581.0,Leerink Initiates Coverage on Novo-Nordisk at Market Perform,2015-08-28 06:25:00-04:00,NVO,neutral
933582.0,"Novo Nordisk Announces Purchase of Calibrium, No Terms Disclosed",2015-08-27 09:05:00-04:00,NVO,negative
933583.0,Novo Nordisk Announces Will Begin Phase 3a Development of Oral Semaglutide,2015-08-26 09:30:00-04:00,NVO,neutral
933584.0,Novo Nordisk  Completes Second And Final Phase 3A Trial With Liraglutide As Adjunct Therapy To Insulin For People With Type 1 Diabetes,2015-08-24 11:36:00-04:00,NVO,neutral
933585.0,"Jim Simons Betting On Microsoft, Colgate-Palmolive, Novo Nordisk & Alaska Air",2015-08-14 15:21:00-04:00,NVO,neutral
933586.0,US Stock Futures Slip Ahead Of Economic Data,2015-08-14 07:11:00-04:00,NVO,neutral
933587.0,Genmab Enters Commercial License Agreement with Novo Nordisk for DuoBody Technology,2015-08-14 06:39:00-04:00,NVO,positive
933588.0,Novo Nordisk Reports Received FDA Approval for FlexPro PenMate for People with Growth Hormone-Related Diseases,2015-07-16 11:56:00-04:00,NVO,positive
933589.0,5 NYSE Healthcare Stocks With The Highest ROI,2015-07-15 09:30:00-04:00,NVO,neutral
933590.0,Novo Nordisk to to Stop Distribution of Once-Daily Basal Insulin Tresiba in Germany Following Failure of Price Negotiations With GKV-Spitzenverband -Reuters,2015-07-01 08:10:00-04:00,NVO,negative
933591.0,Conquering Hemophilia: Novo Nordisk Reports Encouraging Data From Phase III Trial Of NovoEight,2015-06-25 11:17:00-04:00,NVO,positive
933592.0,"Novo Nordisk Says in Phase 3 Trial, Novoeight Provided Long-Term Efficacy, Safety in Prophylaxis, Treatment of Bleeds in People With Haemophilia A",2015-06-24 07:36:00-04:00,NVO,positive
933593.0,5 NYSE Healthcare Stocks With The Highest ROE,2015-06-22 09:29:00-04:00,NVO,neutral
933594.0,5 NYSE Healthcare Stocks With The Highest Operating Margin,2015-06-01 09:09:00-04:00,NVO,neutral
933595.0,Novo Nordisk Says Treatment With Saxenda For 3 Years Reduced Risk of Developing Type 2 Diabetes Compared With Placebo,2015-05-22 10:22:00-04:00,NVO,negative
933596.0,"CHMP Gave Six Recommendations on Extensions of Therapeutic Indication for: Janssen's Simponi and Stelara, Pharmacyclics' Imbruvica, Eisai's Fycompa, BioMarin's Kuvan, Novo's Xultophy",2015-05-22 07:11:00-04:00,NVO,neutral
933597.0,Novo Sells License On Autoimmune Disease To Janssen,2015-05-20 10:10:00-04:00,NVO,neutral
933598.0,Baxter International Cites Novo Nordisk As Respondents In USITC Investigation For Violation Of Section 337 Of Certain Rcombinant Factor VIII Products,2015-05-18 15:47:00-04:00,NVO,negative
933599.0,"Novo Nordisk CFO: U.S. Obesity Market Must Emerge, But It Will Take Time",2015-04-30 13:57:00-04:00,NVO,neutral
933600.0,Novo Nordisk Posts Rise In Profit,2015-04-30 06:06:00-04:00,NVO,positive
933601.0,Novo Nordisk Will Repurchase Shares,2015-04-22 08:35:00-04:00,NVO,positive
933602.0,SocGen Initiates Big Drug/Pharma Names,2015-04-15 12:07:00-04:00,NVO,neutral
933603.0,Top 4 Stocks In The Drug Manufacturers-Other Industry With The Highest Dividend Yield,2015-04-13 05:03:00-04:00,NVO,positive
933604.0,"U.S. FDA Accepts Resubmission Review Of Novo Nordisk's Tresiba, Ryzodeg",2015-04-07 15:44:00-04:00,NVO,positive
933605.0,"Novo Nordisk Says FDA Accepts Tresiba, Ryzodeg Resubmissions for Review",2015-04-07 15:43:00-04:00,NVO,positive
933606.0,Top First Quarter European ETFs,2015-03-31 15:43:00-04:00,NVO,positive
933607.0,"Novo Nordisk Decided to Resubmit NDA's for Tresiba, Ryzodeg in US",2015-03-26 12:25:00-04:00,NVO,neutral
933608.0,Novo Nordisk A/S: Novo Nordisk Completes Phase 3a Trials Comparing Faster-Acting Insulin Aspart With NovoRapid in people with type 1 and type 2 diabetes,2015-03-25 13:25:00-04:00,NVO,neutral
933609.0,Novo Nordisk Receives EC Approval for Saxenda for Treatment of Obesity,2015-03-24 07:34:00-04:00,NVO,positive
933610.0,Stocks Hitting 52-Week Highs,2015-03-20 10:06:00-04:00,NVO,neutral
933611.0,"Novo Nordisk Announces Positive Phase 2 Trial Results, Shares Spike Higher",2015-02-20 11:14:00-05:00,NVO,positive
933612.0,Morning Market Gainers,2015-02-20 09:46:00-05:00,NVO,neutral
933613.0,"Friday #PreMarket Movers: Arista Networks Up, CollabRx Down",2015-02-20 09:00:00-05:00,NVO,neutral
933614.0,Benzinga's Top #PreMarket Gainers,2015-02-20 08:15:00-05:00,NVO,positive
933615.0,Novo Nordisk Announces Positive Results For Phase 2 Trial With Oral Semaglutide In People With Type 2 Diabette,2015-02-20 07:37:00-05:00,NVO,positive
933616.0,Novo Nordisk Announces Positive Phase 2 Trial Results With Oral Semaglutide in People With Type 2 Diabetes,2015-02-20 07:35:00-05:00,NVO,positive
933617.0,"Simons-Founded Renaissance Technologies Buys Apple, Closes Facebook, Trims McDonald's In Q4",2015-02-13 14:19:00-05:00,NVO,neutral
933618.0,Novo Nordisk to Seek IPO of NNIT on NASDAQ OMX Copenhagen,2015-02-09 05:44:00-05:00,NVO,neutral
933619.0,Novo Nordisk Posts Higher Profit,2015-01-30 05:06:00-05:00,NVO,positive
933620.0,"Earnings Scheduled For January 30, 2015",2015-01-30 04:57:00-05:00,NVO,neutral
933621.0,Commerbank Downgrades Novo-Nordisk to Hold,2015-01-28 12:36:00-05:00,NVO,neutral
933622.0,Novo Nordisk Announces Positive Opinion from European Regulatory Authorities for Saxenda,2015-01-22 14:33:00-05:00,NVO,positive
933623.0,5 Obesity Stocks Investors Are Watching,2015-01-14 13:55:00-05:00,NVO,neutral
933624.0,"UPDATE: Xencor is Eligible to Receive Up to $175M in Upfront, Other Payments",2014-12-18 08:11:00-05:00,NVO,neutral
933625.0,"Xencor, Novo Nordisk Report Discovery Collaboration for Xencor's XmAb Bispecific, Immune Inhibitor Technologies",2014-12-18 08:09:00-05:00,NVO,positive
933626.0,How To Profit From The Obesity Epidemic,2014-12-08 16:54:00-05:00,NVO,positive
933627.0,A Look At 4 ETFs From The 4 'Least Corrupt' Countries,2014-12-04 12:13:00-05:00,NVO,neutral
933628.0,"Top Performing Industries For October 30, 2014",2014-10-30 11:10:00-04:00,NVO,positive
933629.0,Novo Nordisk Posts Rise In Profit,2014-10-30 05:36:00-04:00,NVO,positive
933630.0," Novo Nordisk Says Receives Subpoena from US Attorney, Requesting Documents Regarding Potential Manufacturing Issues Within Certain Production Units in Kalundborg, Denmark",2014-10-24 10:58:00-04:00,NVO,positive
933631.0,Top 4 NYSE Stocks In The Drug Manufacturers-Other Industry With The Highest Revenue,2014-10-13 05:22:00-04:00,NVO,positive
933632.0,3 Companies Helping To Keep Diabetes Rates Lower,2014-10-01 14:39:00-04:00,NVO,neutral
933633.0,Top 4 NYSE Stocks In The Drug Manufacturers-Other Industry With The Highest Dividend Yield,2014-08-11 05:20:00-04:00,NVO,positive
933634.0,Top 4 NYSE Stocks In The Drug Manufacturers-Other Industry With The Highest EPS,2014-07-31 04:40:00-04:00,NVO,positive
933635.0,FDA Has Okayed Novo Nordisk's Novoseven RT for Treatment of Glanzmann's - Bloomberg,2014-07-07 13:34:00-04:00,NVO,neutral
933636.0,Top 4 Stocks In The Drug Manufacturers-Other Industry With The Highest Dividend Yield,2014-06-27 05:44:00-04:00,NVO,positive
933637.0,Novo Nordisk Announces DKK 15Bn Buyback,2014-06-23 09:05:00-04:00,NVO,neutral
933638.0,"Novo Nordisk Says Last Year's Investigation Has Ended, Saw No Increased Frequency of Inspections in China - Bloomberg",2014-05-22 09:20:00-04:00,NVO,neutral
933639.0,Google Celebrates Dorothy Hodgkin & Her Contributions To Chemistry,2014-05-12 16:27:00-04:00,NVO,positive
933640.0,"Novo Nordisk Confirms Tresiba, Victoza Receive Positive Opinions from CHMP for Label Updates",2014-03-21 08:42:00-04:00,NVO,positive
933641.0,Citi Added Shares of Novo Nordisk to European 'Focus List',2014-03-20 07:25:00-04:00,NVO,positive
933642.0,UPDATE: Novo Nordisk Reports Results from First Phase 3 Trial with N8-GP,2014-03-19 08:29:00-04:00,NVO,neutral
933643.0,Novo Nordisk Reports Results from First Phase 3 Trial with N8-GP,2014-03-19 08:29:00-04:00,NVO,neutral
933644.0,Top 4 NYSE Stocks In The Drug Manufacturers-Other Industry With The Highest EPS,2014-03-10 05:56:00-04:00,NVO,positive
933645.0,European ETFs Flying Under The Radar ,2014-02-25 15:23:00-05:00,NVO,neutral
933646.0,Bank of America Upgrades Novo Nordisk A/S to Buy,2014-02-25 09:08:00-05:00,NVO,neutral
933647.0,JP Morgan Upgrades Novo Nordisk A/S to Overweight,2014-02-24 11:43:00-05:00,NVO,neutral
933648.0,Top 4 NYSE Stocks In The Drug Manufacturers-Other Industry With The Highest Operating Margin,2014-02-14 04:30:00-05:00,NVO,positive
933649.0,Swedbank Upgrades Novo Nordisk A/S to Buy,2014-01-31 07:56:00-05:00,NVO,neutral
933650.0,Benzinga's Volume Movers,2013-12-03 10:34:00-05:00,NVO,neutral
933651.0,Novo Nordisk Receives FDA Approval for Novolog Flextouch,2013-11-01 15:37:00-04:00,NVO,positive
933652.0,Swedbank Downgrades Novo Nordisk A/S to Neutral,2013-11-01 07:18:00-04:00,NVO,neutral
933653.0,Novo Nordisk Initiates European Share Buyback,2013-10-30 08:38:00-04:00,NVO,positive
933654.0,"Time To Consider Investing In Scandinavia (EWD, EFNL, NORW, EDEN, GXF)",2013-10-25 15:16:00-04:00,NVO,neutral
933655.0,Bloomberg Reporting Novo Nordisk Chief Scientist Thomsen Says In Talks with All US Pharmacy Price Cuts in US,2013-09-26 07:39:00-04:00,NVO,negative
933656.0,Barclays Upgrades Novo Nordisk A/S to Overweight,2013-09-16 07:44:00-04:00,NVO,negative
933657.0,Benzinga's Top Downgrades,2013-09-06 09:00:00-04:00,NVO,positive
933658.0,Swedbank Downgrades Novo Nordisk A/S to Buy,2013-09-06 07:40:00-04:00,NVO,neutral
933659.0,Top 4 Large-Cap Stocks In The Drug Manufacturers-Other Industry With The Highest Cash,2013-09-04 04:12:00-04:00,NVO,positive
933660.0,Novo Nordisk Wins US FDA Clearnace for Novopen Echo,2013-08-21 11:01:00-04:00,NVO,positive
933661.0,"Weekly Preview: Earnings Season Nears The End, China in Focus",2013-08-02 15:28:00-04:00,NVO,neutral
933662.0,Benzinga's Volume Movers,2013-07-01 10:44:00-04:00,NVO,neutral
933663.0,Helvea Upgrades Novo Nordisk A/S to Buy,2013-06-24 09:07:00-04:00,NVO,neutral
933664.0,S&P Upgrades Novo Nordisk from A+ to AA-; Outlook Stable,2013-06-19 10:51:00-04:00,NVO,positive
933665.0,Exane Downgrades Novo Nordisk A/S to Underperform,2013-06-19 07:25:00-04:00,NVO,neutral
933666.0,Novo Nordisk: US Appeals Court Affirms 2001 District Court Decision,2013-06-18 15:16:00-04:00,NVO,neutral
933667.0,Novo Nordisk Says US Court Rules Against it in Patent Case,2013-06-18 15:13:00-04:00,NVO,neutral
933668.0,US Court Rules Novo Nordisk Patent Claim on Prandin Invalid,2013-06-18 11:41:00-04:00,NVO,neutral
933669.0,Benzinga's Top Pre-Market Losers,2013-06-17 08:20:00-04:00,NVO,negative
933670.0,Benzinga's Top Downgrades,2013-06-17 07:57:00-04:00,NVO,positive
933671.0,Bank of America Downgrades Novo Nordisk A/S to Neutral,2013-06-17 07:43:00-04:00,NVO,neutral
933672.0,"FDA Says Considering New Study of Incretin Mimetic Diabetes Drug, Says May Need to Look for Cancer-Link Patterns",2013-06-12 08:18:00-04:00,NVO,neutral
933673.0,Handelsbanken Upgrades Novo Nordisk A/S to Buy,2013-06-11 08:02:00-04:00,NVO,neutral
933674.0,Natixis Upgrades Novo Nordisk A/S to Buy,2013-05-24 07:54:00-04:00,NVO,neutral
933675.0,"Novo Nordisk Posts 28% Rise In Q1 Profit, Lifts Forecast",2013-05-01 04:58:00-04:00,NVO,positive
933676.0,Swedbank Upgrades Novo Nordisk A/S to Buy,2013-04-16 08:48:00-04:00,NVO,neutral
933677.0,Novo Receives US FDA Orphan Drug Designation from Hemophilia B Treatment,2013-03-19 12:03:00-04:00,NVO,neutral
933678.0,JP Morgan Downgrades Novo Nordisk A/S to Underweight,2013-03-18 09:13:00-04:00,NVO,positive
933679.0,These ETFs Have Moving Average Problems,2013-02-27 15:23:00-05:00,NVO,negative
933680.0,Nomura Upgrades Novo Nordisk A/S to Buy,2013-02-12 08:15:00-05:00,NVO,neutral
933681.0,Denmark ETF Decked by Novo Nordisk's Slide ,2013-02-11 11:53:00-05:00,NVO,neutral
933682.0,Morning Market Losers,2013-02-11 10:14:00-05:00,NVO,negative
933683.0,Benzinga's Top Pre-Market Losers,2013-02-11 09:08:00-05:00,NVO,negative
933684.0,Kepler Downgrades Novo Nordisk A/S to Hold,2013-02-11 08:27:00-05:00,NVO,neutral
933685.0,"Novo Nordisk Shares Plunge Following CRL in US for Tresiba, Ryzodeg",2013-02-11 08:27:00-05:00,NVO,positive
933686.0,Natixis Downgrades Novo Nordisk A/S to Neutral,2013-02-11 08:25:00-05:00,NVO,neutral
933687.0,Top 4 NYSE Stocks In The Drug Manufacturers-Other Industry With The Highest Dividend Yield,2013-02-11 01:51:00-05:00,NVO,positive
933688.0,Novo Nordisk Receives FDA Warning Letter Related to Danish Plant Inspection,2013-02-05 09:26:00-05:00,NVO,negative
933689.0,Novo Spokesperson Says Will Introduce Tresiba in Some EU Countries in First Half - Bloomberg,2013-01-29 11:07:00-05:00,NVO,neutral
933690.0,Goldman Sachs Names Novo Nordisk to Conviction Buy List,2013-01-28 09:49:00-05:00,NVO,neutral
933691.0,Top 4 NYSE Stocks In The Drug Manufacturers-Other Industry With The Highest Cash,2012-11-16 01:41:00-05:00,NVO,positive
933692.0,FDA Panel Votes 8-4 to Back Nova Nordisk's Tresiba Approval,2012-11-08 16:00:00-05:00,NVO,positive
933693.0,"FDA Panel Says Novo's Degludec Insulin Needs CV Trial, Votes 12-0",2012-11-08 15:53:00-05:00,NVO,neutral
933694.0,"UPDATE: FDA Advisory Panel Acting Chairperson Says panel Members Generally Agree that Signal of Cardiovascular Risk Was Seen For Novo Nordisk's Degludec Insulin, and That it ""May or May Not Be a Real"" Risk -Reuters",2012-11-08 15:02:00-05:00,NVO,negative
933695.0,Novo Nordisk Spikes Higher,2012-11-08 14:59:00-05:00,NVO,neutral
933696.0,"FDA Panel Says Signal of Cardiovascular Risk For Novo Nordisk's Degludec Insulin ""May or May Not Be Real"" -Reuters",2012-11-08 14:45:00-05:00,NVO,negative
933697.0,Novo Nordisk Spikes to Highs,2012-11-08 14:42:00-05:00,NVO,neutral
933698.0,Jefferies & Company Downgrades Novo Nordisk A/S from Buy to Hold,2012-11-06 11:42:00-05:00,NVO,neutral
933699.0,"Novo Nordisk Posts 35% Rise In Q3 Profit, Lifts 2012 Forecast",2012-10-31 04:07:00-04:00,NVO,positive
933700.0,Top 4 NYSE Stocks In The Drug Manufacturers-Other Industry With The Highest Operating Margin,2012-10-24 03:31:00-04:00,NVO,positive
933701.0,Stocks Hitting 52-Week Highs,2012-10-19 10:21:00-04:00,NVO,neutral
933702.0,Novo Nordisk Stops Development of Vatreptacog,2012-09-28 10:08:00-04:00,NVO,negative
933703.0,"Novo Nordisk Posts 29% Surge In Q2 Profit, Lifts Forecast",2012-08-09 05:42:00-04:00,NVO,positive
933704.0,Novo Nordisk to Initiate Phase 3 Development of Semaglutide,2012-06-21 16:14:00-04:00,NVO,neutral
933705.0,Humana and Novo Nordisk Form Partnership to Improve Quality Outcomes for Patients Fighting Diabetes   ,2012-06-18 10:31:00-04:00,NVO,positive
933706.0,"Novo Says FDA Delay Due to Huge Size of Data Submitted, FDA Delay on Degludec Doesn't Change Much, Sees No Advisory Committee Based on FDA Talks So Far -Bloomberg",2012-06-08 12:51:00-04:00,NVO,negative
933707.0,"The Definitive Scandinavian ETF Guide (EWD, GXF, EDEN)",2012-06-04 00:49:00-04:00,NVO,neutral
933708.0,Novo Nordisk Gets Positive Opinion on Recombinant Factor XIII from European Regulatory Officials,2012-05-25 09:31:00-04:00,NVO,positive
933709.0,Novo Nordisk Announces FDA Approves Levemir® for Expanded Use in Children Two to Five Years of Age with Type 1 Diabetes  ,2012-05-22 09:08:00-04:00,NVO,positive
933710.0,Caisson Biotech Enters into Development and License Agreement with Novo Nordisk   ,2012-05-01 06:40:00-04:00,NVO,positive
933711.0,Novo Nordisk,2012-04-02 18:36:00-04:00,NVO,neutral
933712.0,"Novo Nordisk Stock Up on Diabetes, Obesity Drug News",2012-04-02 14:00:00-04:00,NVO,neutral
933713.0,FDA Approves Levemir(R) Pregnancy Category Change For Women With Diabetes,2012-04-02 09:01:00-04:00,NVO,positive
933714.0,"St. Jude, Novo Nordisk and Other Health Care Stocks Worth a Look Now",2012-03-21 07:20:00-04:00,NVO,positive
933715.0,"Novo Nordisk Reports 19% Rise In Q4 Profit, Lifts Forecast",2012-02-02 05:55:00-05:00,NVO,positive
933716.0,Escaping Europe's Escapades In The Garden of EDEN,2012-01-31 03:00:00-05:00,NVO,positive
933717.0,9 Option Trades on Dividend Stocks & Gold,2011-08-31 00:41:00-04:00,NVO,neutral
933718.0,3 Top Dividend Growth Stocks,2011-08-30 14:08:00-04:00,NVO,positive
933719.0,Top Healthcare and Major Drugs stocks to watch- Sector Performance,2011-05-22 14:55:00-04:00,NVO,positive
933720.0,GlaxoSmithKline and Isis Pharmaceuticals partnership shouldn't be overlooked as a long-term,2011-05-18 06:29:00-04:00,NVO,neutral
933721.0,"CEOWORLD Top 10 Tech Stocks Winning 52-Week Highs- ABB, IBM, ORCL, NVO, BTI, SAP, ERIC, VMW, ACN and MA",2011-04-26 05:29:00-04:00,NVO,positive
933722.0,JP Morgan Downgrades NVO To Neutral,2011-04-11 06:19:00-04:00,NVO,positive
933724.0,Portfolio Construction Philosophy,2011-02-22 08:15:00-05:00,NVO,neutral
933725.0,"Mad Money Lightning Round: Cramer Advises Investors To Buy Apple (NVO, FNSR, ARG, AAPL, OH)",2011-02-14 00:47:00-05:00,NVO,negative
933726.0,Cost Control Helps Amylin Cut Loss - Analyst Blog,2011-01-27 10:31:00-05:00,NVO,negative
933727.0,Cost Control Helps Amylin Cut Loss - Analyst Blog,2011-01-27 10:15:00-05:00,NVO,negative
933728.0,Earnings Preview: Eli Lilly - Analyst Blog,2011-01-25 11:00:00-05:00,NVO,neutral
933729.0,Earnings Preview: Eli Lilly - Analyst Blog,2011-01-25 10:45:00-05:00,NVO,neutral
933730.0,Goldman Ups NVO To Buy,2011-01-25 07:09:00-05:00,NVO,neutral
933731.0,MannKind in Jeopardy - Analyst Blog,2011-01-20 10:01:00-05:00,NVO,negative
933732.0,MannKind in Jeopardy - Analyst Blog,2011-01-20 09:45:00-05:00,NVO,negative
933733.0,Deutsche Bank Downgrades NVO To Sell,2011-01-14 06:05:00-05:00,NVO,neutral
933734.0,"Top 4 Stocks In The Drug Manufacturers-Other Industry With The Highest Dividend Yield (TPI, RELV, TEVA, NVO)",2010-12-30 03:11:00-05:00,NVO,positive
933735.0,Novo Presents Positive Insulin Data - Analyst Blog,2010-12-29 14:33:00-05:00,NVO,positive
933736.0,Novo Presents Positive Insulin Data - Analyst Blog,2010-12-29 14:00:00-05:00,NVO,positive
933737.0,Loss at BIOD Narrower than Expected - Analyst Blog,2010-12-13 13:33:00-05:00,NVO,negative
933738.0,Top Funds Bet on Less Well-Known Trends,2010-12-13 13:05:00-05:00,NVO,positive
933739.0,Loss at BIOD Narrower than Expected - Analyst Blog,2010-12-13 12:58:00-05:00,NVO,negative
933740.0,"Benzinga's Top Upgrades (BRCM, NVO, ARG, PG)",2010-12-10 07:45:00-05:00,NVO,positive
933741.0,Citigroup Upgrades NVO To Buy,2010-12-10 05:54:00-05:00,NVO,neutral
933742.0,Merck Strikes Deal with SmartCells  - Analyst Blog,2010-12-03 11:16:00-05:00,NVO,negative
933743.0,Merck Strikes Deal with SmartCells  - Analyst Blog,2010-12-03 10:11:00-05:00,NVO,negative
933744.0,Morgan Stanley Downgrades NVO To Equal Weight,2010-11-18 07:23:00-05:00,NVO,neutral
933745.0,"Zacks Analyst Blog Highlights: Lions Gate Entertainment, Amylin Pharmaceuticals, Amylin Pharmaceuticals, Eli Lilly, Alkermes and Novo Nordisk       - Press Releases",2010-11-12 10:33:00-05:00,NVO,positive
933746.0,JP Morgan Upgrades NVO To Overweight,2010-10-28 07:28:00-04:00,NVO,neutral
933747.0,"Stocks Rip Higher (SPY, DAL, AMR, NVO, URI)",2010-10-20 12:34:00-04:00,NVO,neutral
933748.0,"Top Performing Industries For October 20 (DAL, NVO, SHZ, CNTY)",2010-10-20 11:16:00-04:00,NVO,positive
933749.0,Novo Nordisk Skyrocketing (NVO),2010-10-20 11:09:00-04:00,NVO,neutral
933750.0,"Two Exceptionally Weak Stocks Today (CBST, NVO)",2010-10-19 13:55:00-04:00,NVO,negative
933751.0,Societe Generale Upgrades NVO To Hold,2010-10-19 06:15:00-04:00,NVO,neutral
933752.0,Novo Nordisk to Invest $73m in Expansion,2010-10-04 10:47:00-04:00,NVO,neutral
933753.0,BMY's Diabetes Candidate Encourages - Analyst Blog,2010-09-21 14:33:00-04:00,NVO,positive
933754.0,Revenues Dip at Alkermes - Analyst Blog,2010-08-09 17:52:00-04:00,NVO,neutral
933755.0,"Top 5 Large-Cap NYSE Stocks In The Healthcare Sector With The Highest Return On Equity (GSK, LLY, AZN, ACL, NVO)",2010-06-07 06:26:00-04:00,NVO,positive
933756.0,NVO Initiated With Hold ,2010-03-31 08:44:00-04:00,NVO,neutral
933757.0,"Top 5 NYSE Stocks In the Healthcare Sector With The Highest ROA (NVO, ACL, HLF, AZN, VAR)",2010-03-03 07:58:00-05:00,NVO,positive
933758.0,Portfolio Tweak,2010-02-12 08:19:00-05:00,NVO,neutral
933759.0,"Stocks That Created New 52-Week Highs (AMLN, CNXT, GOODO, NRGP, INSW)",2010-01-26 14:30:00-05:00,NVO,positive
933760.0,"Benzinga’s Volume Movers (VLTR, AMLN, PRXL, ICLR, ZION)",2010-01-26 14:10:00-05:00,NVO,neutral
933761.0,"FDA Approval For Diabetes Drug Lifts Novo Shares (NVO, AMLN, LLY) ",2010-01-26 08:55:00-05:00,NVO,positive
933762.0,Going Nordic In Search Of ETF Opportunities,2010-01-16 20:20:00-05:00,NVO,positive
933763.0,"Benzinga’s Top Downgrades (PAYX, NVO, TEVA, PVA, PRSC)",2010-01-15 09:33:00-05:00,NVO,positive
933764.0,"Benzinga’s News Roundup (SNTS, MRVL, NVO, AET, CIEN, NVDA)",2009-12-30 09:08:00-05:00,NVO,neutral
933765.0,Novo Nordisk A/S: Transaction in Own Shares,2009-08-17 06:55:00-04:00,NVO,positive
933766.0,16 Companies that Raised Dividends 10% or More for the Last Nine Years,2009-08-16 10:35:00-04:00,NVO,neutral
933767.0,Transaction in Own Shares,2009-08-07 14:34:00-04:00,NVO,positive
933768.0,Novo Nordisk A/S - Transaction in Own Shares,2009-08-07 13:10:00-04:00,NVO,positive
933769.0,Novo Nordisk A/S - Transaction in Own Shares,2009-08-07 11:16:00-04:00,NVO,positive
933770.0,"Liraglutide Lowered Blood Sugar and Weight in African Americans With Type 2 Diabetes, Phase 3 Data Showed",2009-07-27 11:00:00-04:00,NVO,negative
